ID,Description,GeneRatio,BgRatio,RichFactor,FoldEnrichment,zScore,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-168256,Immune System,105/349,759/3769,0.1383399209486166,1.4939918683533984,4.864212592238437,2.1803418980206103e-6,0.0016629969778203606,0.0016561409106097718,PLAUR/SLC11A1/SERPINB1/TNFRSF1B/KIF26A/IL4R/CXCL2/LYZ/CD209/NLRP1/BLNK/FKBP5/CSF2RB/PYGL/HCK/TIMP1/CRISPLD2/IL7/JAK3/NOD1/LIMK1/CSF3/CCL2/LMNB1/BCL6/CISH/POMC/IL1R1/IL1RL1/IL18RAP/GBP1/CR2/CTSD/TTR/DUSP4/F13A1/CDKN1A/MT2A/IRF1/IL1B/CD93/RAC2/LIF/SIGLEC9/TRIM22/CHI3L1/PTPN22/IL15RA/TMBIM1/IL6/PIM1/IRF4/TLR2/FGF2/GPR84/SLC2A5/FCGR2A/S100A8/TIFA/OSMR/IFNA5/FCGR1A/LPCAT1/LY96/FCER1G/FBXW5/C1R/SHC1/GBP2/S100A9/IFI16/CCR1/FBXO40/RAG1/PLD4/B2M/CRK/IL7R/SIGLEC7/RAB24/CD14/FPR2/FPR1/LRG1/SPSB1/SPSB4/TUBB6/CXCR2/ADGRG3/SOCS3/SFTPA2/CD300E/ISG15/CARD9/SERPINA3/CASP4/SERPINA1/C5AR1/MIB2/PNP/CR1/FCGR3A/SIGLEC14/PECAM1/H3C2,105
R-HSA-449147,Signaling by Interleukins,39/349,200/3769,0.195,2.1058882521489974,5.133435101925917,3.3835136883425443e-6,0.0016629969778203606,0.0016561409106097718,TNFRSF1B/IL4R/CXCL2/BLNK/CSF2RB/HCK/TIMP1/IL7/JAK3/NOD1/CSF3/CCL2/LMNB1/BCL6/CISH/POMC/IL1R1/IL1RL1/IL18RAP/DUSP4/F13A1/CDKN1A/IL1B/LIF/IL15RA/IL6/PIM1/IRF4/FGF2/TIFA/OSMR/SHC1/CCR1/RAG1/CRK/IL7R/FPR1/SOCS3/H3C2,39
R-HSA-6798695,Neutrophil degranulation,36/349,187/3769,0.1925133689839572,2.0790340621791823,4.834463374735111,1.1243868026617927e-5,0.0036842407567218077,0.0036690516718437447,PLAUR/SLC11A1/SERPINB1/TNFRSF1B/LYZ/PYGL/CRISPLD2/CTSD/TTR/CD93/SIGLEC9/CHI3L1/TMBIM1/TLR2/GPR84/SLC2A5/FCGR2A/S100A8/LPCAT1/FCER1G/S100A9/B2M/RAB24/CD14/FPR2/FPR1/LRG1/CXCR2/ADGRG3/SERPINA3/SERPINA1/C5AR1/PNP/CR1/SIGLEC14/PECAM1,36
R-HSA-168249,Innate Immune System,60/349,389/3769,0.15424164524421594,1.665721378009885,4.4285755858960565,2.444643146271409e-5,0.005399539752075866,0.005377278973529536,PLAUR/SLC11A1/SERPINB1/TNFRSF1B/LYZ/CD209/NLRP1/PYGL/HCK/CRISPLD2/NOD1/LIMK1/CR2/CTSD/TTR/DUSP4/IL1B/CD93/RAC2/SIGLEC9/CHI3L1/TMBIM1/TLR2/GPR84/SLC2A5/FCGR2A/S100A8/TIFA/IFNA5/FCGR1A/LPCAT1/LY96/FCER1G/C1R/SHC1/S100A9/IFI16/PLD4/B2M/CRK/RAB24/CD14/FPR2/FPR1/LRG1/CXCR2/ADGRG3/SFTPA2/CD300E/ISG15/CARD9/SERPINA3/CASP4/SERPINA1/C5AR1/PNP/CR1/FCGR3A/SIGLEC14/PECAM1,60
R-HSA-6783783,Interleukin-10 signaling,11/349,29/3769,0.3793103448275862,4.096334354312814,5.346457965826342,2.746459690781214e-5,0.005399539752075866,0.005377278973529536,TNFRSF1B/CXCL2/TIMP1/CSF3/CCL2/IL1R1/IL1B/LIF/IL6/CCR1/FPR1,11
R-HSA-1280215,Cytokine Signaling in Immune system,50/349,309/3769,0.16181229773462782,1.747480086423531,4.3802200113811836,3.564485073718223e-5,0.0058398147124416894,0.0058157388044876275,TNFRSF1B/IL4R/CXCL2/BLNK/FKBP5/CSF2RB/HCK/TIMP1/IL7/JAK3/NOD1/CSF3/CCL2/LMNB1/BCL6/CISH/POMC/IL1R1/IL1RL1/IL18RAP/GBP1/DUSP4/F13A1/CDKN1A/MT2A/IRF1/IL1B/LIF/TRIM22/IL15RA/IL6/PIM1/IRF4/FGF2/TIFA/OSMR/IFNA5/FCGR1A/SHC1/GBP2/CCR1/RAG1/B2M/CRK/IL7R/FPR1/TUBB6/SOCS3/ISG15/H3C2,50
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,16/349,61/3769,0.26229508196721313,2.8326365728780125,4.609210171050812,8.6164307198608e-5,0.012099930568033095,0.012050045969128639,TNFRSF1B/IL4R/TIMP1/JAK3/CCL2/BCL6/POMC/F13A1/CDKN1A/IL1B/LIF/IL6/PIM1/IRF4/FGF2/SOCS3,16
R-HSA-5660526,Response to metal ions,5/349,7/3769,0.7142857142857143,7.713876381498158,5.6789503598593365,1.1888865282133477e-4,0.01460844321542151,0.01454821672682123,SNCB/MT2A/MT1X/MT1A/MT1M,5
R-HSA-375276,Peptide ligand-binding receptors,21/349,105/3769,0.2,2.1598853868194845,3.85023379285782,4.75992080198588e-4,0.05156699785599631,0.05135440167701084,EDN1/CXCL2/NTSR1/CCL2/POMC/PRLHR/HCRTR1/EDN3/MCHR1/HCRTR2/CCR1/BDKRB2/TRH/FPR2/FPR1/CXCR2/CCR10/QRFPR/C5AR1/ACKR1/SSTR3,21
R-HSA-500792,GPCR ligand binding,38/349,240/3769,0.15833333333333333,1.709909264565425,3.630260105996627,5.245879741200032e-4,0.05156699785599631,0.05135440167701084,WNT8A/EDN1/CXCL2/NTSR1/CCL2/CALCA/POMC/PRLHR/HCRTR1/EDN3/ADGRE2/MCHR1/PLPPR3/RAMP2/HCRTR2/ADCYAP1/WNT9A/ADM/ADRA2A/WNT7A/CCR1/GRM2/BDKRB2/DRD5/TRH/FPR2/FPR1/P2RY6/ADGRE1/FZD8/GPR4/HTR1A/CXCR2/CCR10/QRFPR/C5AR1/ACKR1/SSTR3,38
R-HSA-5661231,Metallothioneins bind metals,4/349,6/3769,0.6666666666666666,7.199617956064947,4.854321666291757,9.325374517996434e-4,0.07807157767244345,0.07774971059096474,MT2A/MT1X/MT1A/MT1M,4
R-HSA-5686938,Regulation of TLR by endogenous ligand,6/349,14/3769,0.42857142857142855,4.628325828898895,4.344306270299197,9.530609685344063e-4,0.07807157767244345,0.07774971059096474,TLR2/S100A8/LY96/S100A9/CD14/SFTPA2,6
R-HSA-5602498,MyD88 deficiency (TLR2/4),5/349,10/3769,0.5,5.399713467048711,4.449829168385435,0.0011267123233967254,0.08519678568453701,0.08484554338129188,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-1236974,ER-Phagosome pathway,6/349,15/3769,0.4,4.319770773638969,4.11492287833897,0.0014659624161171096,0.09606940366954125,0.09567333663080085,TLR2/S100A8/LY96/S100A9/B2M/CD14,6
R-HSA-1266695,Interleukin-7 signaling,6/349,15/3769,0.4,4.319770773638969,4.11492287833897,0.0014659624161171096,0.09606940366954125,0.09567333663080085,IL7/JAK3/CISH/RAG1/IL7R/H3C2,6
R-HSA-5603041,IRAK4 deficiency (TLR2/4),5/349,11/3769,0.45454545454545453,4.908830424589737,4.146864951719096,0.0019100614652925443,0.11665333378313454,0.11617240500970728,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-2029481,FCGR activation,4/349,7/3769,0.5714285714285714,6.1711011051985265,4.373989751012255,0.0020174025171040564,0.11665333378313454,0.11617240500970728,HCK/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-6803157,Antimicrobial peptides,5/349,12/3769,0.4166666666666667,4.4997612225405925,3.878497785827483,0.003028357431032514,0.16538196415027565,0.16470014098597885,SLC11A1/LYZ/TLR2/S100A8/S100A9,5
R-HSA-6783589,Interleukin-6 family signaling,4/349,8/3769,0.5,5.399713467048711,3.9789898207737657,0.0037418102455075808,0.19358944585968169,0.19279133120897787,LIF/IL6/OSMR/SOCS3,4
R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",6/349,18/3769,0.3333333333333333,3.5998089780324736,3.5315004601622078,0.004278079869058068,0.21026762556420406,0.20940075148547388,BLNK/CSF2RB/HCK/JAK3/SHC1/CRK,6
R-HSA-112409,RAF-independent MAPK1/3 activation,4/349,9/3769,0.4444444444444444,4.799745304043298,3.6453306462785613,0.006247772191894785,0.23157728142865708,0.23062255365278267,DUSP4/IL6/DUSP5/DUSP2,4
R-HSA-140534,Caspase activation via Death Receptors in the presence of ligand,4/349,9/3769,0.4444444444444444,4.799745304043298,3.6453306462785613,0.006247772191894785,0.23157728142865708,0.23062255365278267,TNFRSF10B/TNFSF10/LY96/CD14,4
R-HSA-9674555,Signaling by CSF3 (G-CSF),4/349,9/3769,0.4444444444444444,4.799745304043298,3.6453306462785613,0.006247772191894785,0.23157728142865708,0.23062255365278267,HCK/CSF3/SHC1/SOCS3,4
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),27/349,179/3769,0.15083798882681565,1.628963839221399,2.753975524058645,0.0067134404090548015,0.23157728142865708,0.23062255365278267,EDN1/CXCL2/NTSR1/CCL2/POMC/PRLHR/HCRTR1/EDN3/MCHR1/PLPPR3/HCRTR2/ADRA2A/CCR1/BDKRB2/DRD5/TRH/FPR2/FPR1/P2RY6/GPR4/HTR1A/CXCR2/CCR10/QRFPR/C5AR1/ACKR1/SSTR3,27
R-HSA-193697,p75NTR regulates axonogenesis,3/349,5/3769,0.6,6.479656160458453,3.9162337908732967,0.006831883175413078,0.23157728142865708,0.23062255365278267,RTN4R/NGFR/LINGO1,3
R-HSA-2691230,Signaling by NOTCH1 HD Domain Mutants in Cancer,3/349,5/3769,0.6,6.479656160458453,3.9162337908732967,0.006831883175413078,0.23157728142865708,0.23062255365278267,NOTCH1/JAG2/MIB2,3
R-HSA-2691232,Constitutive Signaling by NOTCH1 HD Domain Mutants,3/349,5/3769,0.6,6.479656160458453,3.9162337908732967,0.006831883175413078,0.23157728142865708,0.23062255365278267,NOTCH1/JAG2/MIB2,3
R-HSA-389397,Orexin and neuropeptides FF and QRFP bind to their respective receptors,3/349,5/3769,0.6,6.479656160458453,3.9162337908732967,0.006831883175413078,0.23157728142865708,0.23062255365278267,HCRTR1/HCRTR2/QRFPR,3
R-HSA-8983432,Interleukin-15 signaling,3/349,5/3769,0.6,6.479656160458453,3.9162337908732967,0.006831883175413078,0.23157728142865708,0.23062255365278267,JAK3/IL15RA/SHC1,3
R-HSA-877300,Interferon gamma signaling,9/349,40/3769,0.225,2.42987106017192,2.903927622827208,0.00925958387468508,0.3027554118170228,0.3015072366973617,GBP1/MT2A/IRF1/TRIM22/IRF4/FCGR1A/GBP2/B2M/SOCS3,9
R-HSA-1236975,Antigen processing-Cross presentation,7/349,27/3769,0.25925925925925924,2.79985142735859,2.9979318411395517,0.009547729162083119,0.3027554118170228,0.3015072366973617,TLR2/S100A8/FCGR1A/LY96/S100A9/B2M/CD14,7
R-HSA-419812,Calcitonin-like ligand receptors,3/349,6/3769,0.5,5.399713467048711,3.4449904106875646,0.012731228899026519,0.39108743774197086,0.38947509460837704,CALCA/RAMP2/ADM,3
R-HSA-372790,Signaling by GPCR,46/349,367/3769,0.12534059945504086,1.3536066456906848,2.277410945335679,0.0171708279522373,0.5114825417287656,0.5093738435591927,WNT8A/TRPC7/EDN1/CXCL2/NTSR1/CCL2/CALCA/POMC/RGS2/PRLHR/HCRTR1/EDN3/ADGRE2/MCHR1/PLPPR3/ARHGEF16/RAMP2/GPR45/HCRTR2/GPR84/ADCYAP1/RGS16/WNT9A/ADM/ADRA2A/WNT7A/GNA14/SHC1/CCR1/GRM2/BDKRB2/DRD5/TRH/FPR2/FPR1/P2RY6/ADGRE1/FZD8/GPR4/HTR1A/CXCR2/CCR10/QRFPR/C5AR1/ACKR1/SSTR3,46
R-HSA-5668914,Diseases of metabolism,15/349,91/3769,0.16483516483516483,1.7801253188072672,2.4062143600369903,0.018563867853217213,0.5234247822516775,0.5212668495947531,CSF2RB/POMC/CHST3/CHSY1/THBS1/CYP1B1/NOTCH1/ADAMTS9/OPLAH/SFTPA2/CYP26C1/ADAMTSL2/PNP/ACY1/BCKDHA,15
R-HSA-5260271,Diseases of Immune System,5/349,18/3769,0.2777777777777778,2.9998408150270617,2.716522182281277,0.020590480916587217,0.5234247822516775,0.5212668495947531,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-5602358,Diseases associated with the TLR signaling cascade,5/349,18/3769,0.2777777777777778,2.9998408150270617,2.716522182281277,0.020590480916587217,0.5234247822516775,0.5212668495947531,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-428643,Organic anion transporters,3/349,7/3769,0.42857142857142855,4.628325828898895,3.069029142165173,0.020766598685468388,0.5234247822516775,0.5212668495947531,SLC17A6/SLC25A1/SLC25A10,3
R-HSA-75158,TRAIL  signaling,3/349,7/3769,0.42857142857142855,4.628325828898895,3.069029142165173,0.020766598685468388,0.5234247822516775,0.5212668495947531,TNFRSF10B/TNFSF10/TNFRSF10D,3
R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,3/349,7/3769,0.42857142857142855,4.628325828898895,3.069029142165173,0.020766598685468388,0.5234247822516775,0.5212668495947531,HCK/CSF3/SOCS3,3
R-HSA-373080,Class B/2 (Secretin family receptors),10/349,54/3769,0.18518518518518517,1.9998938766847076,2.3638857746026245,0.024183183027560933,0.5943017229023099,0.591851584621886,WNT8A/CALCA/ADGRE2/RAMP2/ADCYAP1/WNT9A/ADM/WNT7A/ADGRE1/FZD8,10
R-HSA-5357769,Caspase activation via extrinsic apoptotic signalling pathway,4/349,13/3769,0.3076923076923077,3.3229005951068995,2.6797520826172603,0.026320980052990037,0.6310615461485173,0.6284598574911614,TNFRSF10B/TNFSF10/LY96/CD14,4
R-HSA-909733,Interferon alpha/beta signaling,6/349,26/3769,0.23076923076923078,2.492175446330174,2.438662821773671,0.028194847665861163,0.6445473315242215,0.6418900447797035,IRF1/IRF4/IFNA5/GBP2/SOCS3/ISG15,6
R-HSA-9833110,RSV-host interactions,6/349,26/3769,0.23076923076923078,2.492175446330174,2.438662821773671,0.028194847665861163,0.6445473315242215,0.6418900447797035,CD209/TLR2/IFNA5/LY96/CD14/ISG15,6
R-HSA-2892247,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",3/349,8/3769,0.375,4.049785100286533,2.7581486750153545,0.03098147174944485,0.662060581080528,0.659331092150657,FGF2/ZIC3/CRIPTO,3
R-HSA-6803211,TP53 Regulates Transcription of Death Receptors and Ligands,3/349,8/3769,0.375,4.049785100286533,2.7581486750153545,0.03098147174944485,0.662060581080528,0.659331092150657,TNFRSF10B/TNFRSF10D/TNFRSF10C,3
R-HSA-9827857,Specification of primordial germ cells,3/349,8/3769,0.375,4.049785100286533,2.7581486750153545,0.03098147174944485,0.662060581080528,0.659331092150657,PRDM1/PDPN/SOX17,3
R-HSA-2029485,Role of phospholipids in phagocytosis,4/349,14/3769,0.2857142857142857,3.0855505525992633,2.4970939132642607,0.034228676831338574,0.7009747776084546,0.6980848564286156,FCGR2A/FCGR1A/PLD4/FCGR3A,4
R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,4/349,14/3769,0.2857142857142857,3.0855505525992633,2.4970939132642607,0.034228676831338574,0.7009747776084546,0.6980848564286156,RAC2/S100A8/S100A9/NOXA1,4
R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,7/349,35/3769,0.2,2.1598853868194845,2.2019986569680823,0.03811749280638345,0.7646835801770394,0.7615310055840303,HCK/LIMK1/FCGR2A/FCGR1A/PLD4/CRK/FCGR3A,7
R-HSA-2122948,Activated NOTCH1 Transmits Signal to the Nucleus,3/349,9/3769,0.3333333333333333,3.5998089780324736,2.4941575247181174,0.04334832152821988,0.8194500011969258,0.8160716401061637,NOTCH1/JAG2/MIB2,3
R-HSA-425410,Metal ion SLC transporters,3/349,9/3769,0.3333333333333333,3.5998089780324736,2.4941575247181174,0.04334832152821988,0.8194500011969258,0.8160716401061637,SLC11A1/CP/SLC39A14,3
R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,3/349,9/3769,0.3333333333333333,3.5998089780324736,2.4941575247181174,0.04334832152821988,0.8194500011969258,0.8160716401061637,GADD45A/CDK2/CDKN1A,3
R-HSA-380108,Chemokine receptors bind chemokines,5/349,22/3769,0.22727272727272727,2.4544152122948684,2.185309781849534,0.04663548257315467,0.8649562145171893,0.8613902441516156,CXCL2/CCL2/CCR1/CXCR2/CCR10,5
R-HSA-9820952,Respiratory Syncytial Virus Infection Pathway,6/349,30/3769,0.2,2.1598853868194845,2.0372910587757413,0.05323722133165158,0.8844328679403665,0.8807866008294061,CD209/TLR2/IFNA5/LY96/CD14/ISG15,6
R-HSA-5579029,Metabolic disorders of biological oxidation enzymes,4/349,16/3769,0.25,2.6998567335243555,2.1763970900620127,0.05374295990448731,0.8844328679403665,0.8807866008294061,CYP1B1/OPLAH/CYP26C1/ACY1,4
R-HSA-354192,Integrin signaling,3/349,10/3769,0.3,3.2398280802292265,2.2653412314730668,0.05778539699564545,0.8844328679403665,0.8807866008294061,SHC1/CRK/ITGB3,3
R-HSA-452723,Transcriptional regulation of pluripotent stem cells,3/349,10/3769,0.3,3.2398280802292265,2.2653412314730668,0.05778539699564545,0.8844328679403665,0.8807866008294061,FGF2/ZIC3/CRIPTO,3
R-HSA-912526,Interleukin receptor SHC signaling,3/349,10/3769,0.3,3.2398280802292265,2.2653412314730668,0.05778539699564545,0.8844328679403665,0.8807866008294061,CSF2RB/JAK3/SHC1,3
R-HSA-912631,Regulation of signaling by CBL,3/349,10/3769,0.3,3.2398280802292265,2.2653412314730668,0.05778539699564545,0.8844328679403665,0.8807866008294061,BLNK/HCK/CRK,3
R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,9/349,55/3769,0.16363636363636364,1.7671789528523052,1.830678926384121,0.06321618176728398,0.8844328679403665,0.8807866008294061,NOD1/DUSP4/TLR2/S100A8/TIFA/LY96/S100A9/CD14/SFTPA2,9
R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,9/349,55/3769,0.16363636363636364,1.7671789528523052,1.830678926384121,0.06321618176728398,0.8844328679403665,0.8807866008294061,NOD1/DUSP4/TLR2/S100A8/TIFA/LY96/S100A9/CD14/SFTPA2,9
R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,5/349,24/3769,0.20833333333333334,2.2498806112702963,1.9620196313701754,0.06470507959535456,0.8844328679403665,0.8807866008294061,LIMK1/FCGR2A/FCGR1A/CRK/FCGR3A,5
R-HSA-5218859,Regulated Necrosis,5/349,24/3769,0.20833333333333334,2.2498806112702963,1.9620196313701754,0.06470507959535456,0.8844328679403665,0.8807866008294061,TNFRSF10B/TNFSF10/IRF1/IL1B/CASP4,5
R-HSA-9031628,NGF-stimulated transcription,5/349,24/3769,0.20833333333333334,2.2498806112702963,1.9620196313701754,0.06470507959535456,0.8844328679403665,0.8807866008294061,LYL1/F3/VGF/EGR4/ARC,5
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),4/349,17/3769,0.23529411764705882,2.5410416315523343,2.03405421732917,0.06533794498174963,0.8844328679403665,0.8807866008294061,TFPI/F3/F13A1/THBD,4
R-HSA-76009,Platelet Aggregation (Plug Formation),4/349,17/3769,0.23529411764705882,2.5410416315523343,2.03405421732917,0.06533794498174963,0.8844328679403665,0.8807866008294061,ADRA2A/SHC1/CRK/ITGB3,4
R-HSA-198323,AKT phosphorylates targets in the cytosol,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,BAD/CDKN1A,2
R-HSA-199220,Vitamin B5 (pantothenate) metabolism,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,VNN2/NUDT8,2
R-HSA-444473,Formyl peptide receptors bind formyl peptides and many other ligands,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,FPR2/FPR1,2
R-HSA-75205,Dissolution of Fibrin Clot,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,PLAUR/SERPINB8,2
R-HSA-8877330,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,RUNX1/CR1,2
R-HSA-8939242,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,RUNX1/SOCS3,2
R-HSA-937041,IKK complex recruitment mediated by RIP1,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,LY96/CD14,2
R-HSA-9614657,FOXO-mediated transcription of cell death genes,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,BCL6/CITED2,2
R-HSA-9675126,Diseases of mitotic cell cycle,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,CDK2/CDKN1A,2
R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,CDK2/CDKN1A,2
R-HSA-9702518,STAT5 activation downstream of FLT3 ITD mutants,2/349,5/3769,0.4,4.319770773638969,2.3725938454851505,0.07082363333011334,0.8844328679403665,0.8807866008294061,CDKN1A/PIM1,2
R-HSA-109582,Hemostasis,35/349,296/3769,0.11824324324324324,1.276959265856114,1.585493517593885,0.07259686088104737,0.8844328679403665,0.8807866008294061,TFPI/SELE/PLAUR/KIF26A/TRPC7/ATP2A3/ANGPT2/TIMP1/F3/TNFRSF10B/SRGN/CDK2/F13A1/IRF1/RAC2/THBS1/IFNA5/ADRA2A/GNA14/F11R/FCER1G/SHC1/SH2B2/PDPN/SERPINB8/CRK/TNFRSF10D/TUBB6/THBD/MAFF/SERPINA3/SERPINA1/ITGB3/PECAM1/H3C2,35
R-HSA-5620971,Pyroptosis,3/349,11/3769,0.2727272727272727,2.9452982547538418,2.0637603264986146,0.07417065190729862,0.8844328679403665,0.8807866008294061,IRF1/IL1B/CASP4,3
R-HSA-9614085,FOXO-mediated transcription,5/349,25/3769,0.2,2.1598853868194845,1.8585415241339993,0.07501696163699788,0.8844328679403665,0.8807866008294061,BCL6/POMC/GADD45A/CDKN1A/CITED2,5
R-HSA-2172127,DAP12 interactions,4/349,18/3769,0.2222222222222222,2.399872652021649,1.9015439044003464,0.0781229347146532,0.8844328679403665,0.8807866008294061,SHC1/B2M/CD300E/SIGLEC14,4
R-HSA-3000170,Syndecan interactions,4/349,18/3769,0.2222222222222222,2.399872652021649,1.9015439044003464,0.0781229347146532,0.8844328679403665,0.8807866008294061,COL5A3/THBS1/FGF2/ITGB3,4
R-HSA-913531,Interferon Signaling,13/349,92/3769,0.14130434782608695,1.5260059798181138,1.6315218245748246,0.07922739187696524,0.8844328679403665,0.8807866008294061,FKBP5/GBP1/MT2A/IRF1/TRIM22/IRF4/IFNA5/FCGR1A/GBP2/B2M/TUBB6/SOCS3/ISG15,13
R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,9/349,58/3769,0.15517241379310345,1.6757731449461515,1.6566263166625792,0.08312956060296929,0.8844328679403665,0.8807866008294061,SLC7A2/SLC38A5/SLC17A6/SLC25A1/SLC1A5/SLC26A1/SLC9A4/SLC25A10/SLC4A5,9
R-HSA-381119,Unfolded Protein Response (UPR),4/349,19/3769,0.21052631578947367,2.273563565073141,1.7776117001871492,0.09205383581737861,0.8844328679403665,0.8807866008294061,CCL2/PARN/CREB3L1/SHC1,4
R-HSA-977606,Regulation of Complement cascade,4/349,19/3769,0.21052631578947367,2.273563565073141,1.7776117001871492,0.09205383581737861,0.8844328679403665,0.8807866008294061,CR2/C1R/C5AR1/CR1,4
R-HSA-201556,Signaling by ALK,3/349,12/3769,0.25,2.6998567335243555,1.8838115396947432,0.09235323683261853,0.8844328679403665,0.8807866008294061,PRDM1/JAK3/SHC1,3
R-HSA-5683826,Surfactant metabolism,3/349,12/3769,0.25,2.6998567335243555,1.8838115396947432,0.09235323683261853,0.8844328679403665,0.8807866008294061,CSF2RB/ADRA2A/SFTPA2,3
R-HSA-9759475,Regulation of CDH11 Expression and Function,3/349,12/3769,0.25,2.6998567335243555,1.8838115396947432,0.09235323683261853,0.8844328679403665,0.8807866008294061,ADAM33/PRDM8/ANGPTL4,3
R-HSA-73887,Death Receptor Signaling,9/349,60/3769,0.15,1.6199140401146133,1.5460865020328203,0.09828619274459936,0.8844328679403665,0.8807866008294061,BAD/RTN4R/NGFR/TNFRSF10B/TNFSF10/ARHGEF16/LINGO1/TNFRSF10D/MIB2,9
R-HSA-1614558,Degradation of cysteine and homocysteine,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,GADL1/SLC25A10,2
R-HSA-174403,Glutathione synthesis and recycling,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CHAC1/OPLAH,2
R-HSA-187577,SCF(Skp2)-mediated degradation of p27/p21,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CDK2/CDKN1A,2
R-HSA-2022377,Metabolism of Angiotensinogen to Angiotensins,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CTSD/CPB1,2
R-HSA-209952,Peptide hormone biosynthesis,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,POMC/INHBB,2
R-HSA-210990,PECAM1 interactions,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,ITGB3/PECAM1,2
R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,FCER1G/SHC1,2
R-HSA-2979096,NOTCH2 Activation and Transmission of Signal to the Nucleus,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,JAG2/MIB2,2
R-HSA-3371378,Regulation by c-FLIP,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,TNFRSF10B/TNFSF10,2
R-HSA-372708,p130Cas linkage to MAPK signaling for integrins,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CRK/ITGB3,2
R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CCL2/PARN,2
R-HSA-381042,PERK regulates gene expression,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CCL2/PARN,2
R-HSA-5218900,CASP8 activity is inhibited,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,TNFRSF10B/TNFSF10,2
R-HSA-5620922,BBSome-mediated cargo-targeting to cilium,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,MCHR1/SSTR3,2
R-HSA-622323,Presynaptic nicotinic acetylcholine receptors,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CHRNA4/CHRNA6,2
R-HSA-629597,Highly calcium permeable nicotinic acetylcholine receptors,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,CHRNA4/CHRNA6,2
R-HSA-6788467,IL-6-type cytokine receptor ligand interactions,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,LIF/OSMR,2
R-HSA-69416,Dimerization of procaspase-8,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,TNFRSF10B/TNFSF10,2
R-HSA-9020558,Interleukin-2 signaling,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,JAK3/SHC1,2
R-HSA-9762292,Regulation of CDH11 function,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,ADAM33/ANGPTL4,2
R-HSA-9909505,Modulation of host responses by IFN-stimulated genes,2/349,6/3769,0.3333333333333333,3.5998089780324736,2.0356591550833714,0.09986983554565684,0.8844328679403665,0.8807866008294061,FKBP5/ISG15,2
R-HSA-451927,Interleukin-2 family signaling,4/349,20/3769,0.2,2.1598853868194845,1.6612211892833895,0.10707482993139252,0.9265222212670293,0.9227024316307086,CSF2RB/JAK3/IL15RA/SHC1,4
R-HSA-163125,Post-translational modification: synthesis of GPI-anchored proteins,6/349,36/3769,0.16666666666666666,1.7999044890162368,1.5403361110196205,0.11005289659981082,0.9265222212670293,0.9227024316307086,PLAUR/VNN2/LYPD6B/MELTF/LY6H/NTNG2,6
R-HSA-198725,Nuclear Events (kinase and transcription factor activation),6/349,36/3769,0.16666666666666666,1.7999044890162368,1.5403361110196205,0.11005289659981082,0.9265222212670293,0.9227024316307086,LYL1/F3/DUSP4/VGF/EGR4/ARC,6
R-HSA-186797,Signaling by PDGF,5/349,28/3769,0.17857142857142858,1.9284690953745396,1.5750985135803892,0.1108830755737003,0.9265222212670293,0.9227024316307086,COL5A3/COL9A3/THBS1/CRK/COL4A1,5
R-HSA-76002,"Platelet activation, signaling and aggregation",16/349,125/3769,0.128,1.38232664756447,1.3885307392170254,0.11190694393619093,0.9265222212670293,0.9227024316307086,TRPC7/TIMP1/SRGN/F13A1/RAC2/THBS1/ADRA2A/GNA14/FCER1G/SHC1/PDPN/CRK/SERPINA3/SERPINA1/ITGB3/PECAM1,16
R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,8/349,53/3769,0.1509433962264151,1.630102178731686,1.4755915886688724,0.1119952272905501,0.9265222212670293,0.9227024316307086,NOD1/DUSP4/TLR2/S100A8/TIFA/LY96/S100A9/CD14,8
R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,8/349,53/3769,0.1509433962264151,1.630102178731686,1.4755915886688724,0.1119952272905501,0.9265222212670293,0.9227024316307086,NOD1/DUSP4/TLR2/S100A8/TIFA/LY96/S100A9/CD14,8
R-HSA-3238698,WNT ligand biogenesis and trafficking,3/349,13/3769,0.23076923076923078,2.492175446330174,1.7214082549880305,0.1121629138665071,0.9265222212670293,0.9227024316307086,WNT8A/WNT9A/WNT7A,3
R-HSA-983169,Class I MHC mediated antigen processing & presentation,13/349,98/3769,0.1326530612244898,1.4325770422782294,1.385924014219246,0.11609220700954168,0.9509886624198288,0.9470680045515242,TLR2/S100A8/FCGR1A/LY96/FBXW5/S100A9/FBXO40/B2M/CD14/SPSB1/SPSB4/SOCS3/MIB2,13
R-HSA-425407,SLC-mediated transmembrane transport,15/349,117/3769,0.1282051282051282,1.3845419146278743,1.349666095539907,0.11984295444872133,0.9736002001908517,0.9695863213337177,SLC7A2/SLC38A5/SLC11A1/CP/SLC17A6/SLC25A1/SLC39A14/SLC1A5/SLC26A1/RUNX1/SLC29A4/SLC13A4/SLC9A4/SLC25A10/SLC4A5,15
R-HSA-1474228,Degradation of the extracellular matrix,10/349,72/3769,0.1388888888888889,1.4999204075135308,1.3680359057600968,0.1247849172606841,0.9935576120215243,0.9894614543877684,COL5A3/COL9A3/TIMP1/CAPN15/CTSD/SCUBE1/ADAMTS9/COL8A2/COL4A1/MMP17,10
R-HSA-416476,G alpha (q) signalling events,16/349,128/3769,0.125,1.3499283667621778,1.2865566165265245,0.1304417953328246,0.9935576120215243,0.9894614543877684,TRPC7/EDN1/NTSR1/RGS2/HCRTR1/EDN3/MCHR1/HCRTR2/RGS16/GNA14/BDKRB2/TRH/FPR2/P2RY6/GPR4/QRFPR,16
R-HSA-1912420,Pre-NOTCH Processing in Golgi,2/349,7/3769,0.2857142857142857,3.0855505525992633,1.7640685333180908,0.1315111302897321,0.9935576120215243,0.9894614543877684,ATP2A3/NOTCH1,2
R-HSA-69563,p53-Dependent G1 DNA Damage Response,2/349,7/3769,0.2857142857142857,3.0855505525992633,1.7640685333180908,0.1315111302897321,0.9935576120215243,0.9894614543877684,CDK2/CDKN1A,2
R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,2/349,7/3769,0.2857142857142857,3.0855505525992633,1.7640685333180908,0.1315111302897321,0.9935576120215243,0.9894614543877684,CDK2/CDKN1A,2
R-HSA-912694,Regulation of IFNA/IFNB signaling,2/349,7/3769,0.2857142857142857,3.0855505525992633,1.7640685333180908,0.1315111302897321,0.9935576120215243,0.9894614543877684,IFNA5/SOCS3,2
R-HSA-9617828,FOXO-mediated transcription of cell cycle genes,2/349,7/3769,0.2857142857142857,3.0855505525992633,1.7640685333180908,0.1315111302897321,0.9935576120215243,0.9894614543877684,GADD45A/CDKN1A,2
R-HSA-187037,Signaling by NTRK1 (TRKA),9/349,64/3769,0.140625,1.5186694126074498,1.3367236304514134,0.13304051114535057,0.9935576120215243,0.9894614543877684,LYL1/F3/DUSP4/VGF/EGR4/ADCYAP1/SHC1/CRK/ARC,9
R-HSA-168638,NOD1/2 Signaling Pathway,3/349,14/3769,0.21428571428571427,2.3141629144494473,1.5734877347467928,0.1334177057851894,0.9935576120215243,0.9894614543877684,NOD1/CARD9/CASP4,3
R-HSA-9759476,Regulation of Homotypic Cell-Cell Adhesion,3/349,14/3769,0.21428571428571427,2.3141629144494473,1.5734877347467928,0.1334177057851894,0.9935576120215243,0.9894614543877684,ADAM33/PRDM8/ANGPTL4,3
R-HSA-9764260,Regulation of Expression and Function of Type II Classical Cadherins,3/349,14/3769,0.21428571428571427,2.3141629144494473,1.5734877347467928,0.1334177057851894,0.9935576120215243,0.9894614543877684,ADAM33/PRDM8/ANGPTL4,3
R-HSA-166658,Complement cascade,4/349,22/3769,0.18181818181818182,1.9635321698358947,1.447740822613312,0.14011699005856856,0.995170154694874,0.9910673490027657,CR2/C1R/C5AR1/CR1,4
R-HSA-9664323,FCGR3A-mediated IL10 synthesis,4/349,22/3769,0.18181818181818182,1.9635321698358947,1.447740822613312,0.14011699005856856,0.995170154694874,0.9910673490027657,HCK/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-202733,Cell surface interactions at the vascular wall,10/349,74/3769,0.13513513513513514,1.4593820181212733,1.274787326870904,0.14236022980932753,0.995170154694874,0.9910673490027657,SELE/ANGPT2/TNFRSF10B/F11R/FCER1G/SHC1/TNFRSF10D/THBD/ITGB3/PECAM1,10
R-HSA-114604,GPVI-mediated activation cascade,3/349,15/3769,0.2,2.1598853868194845,1.437701347446587,0.15593004930740498,0.995170154694874,0.9910673490027657,RAC2/FCER1G/PDPN,3
R-HSA-5675221,Negative regulation of MAPK pathway,3/349,15/3769,0.2,2.1598853868194845,1.437701347446587,0.15593004930740498,0.995170154694874,0.9910673490027657,DUSP4/DUSP5/DUSP2,3
R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",4/349,23/3769,0.17391304347826086,1.8781612059299864,1.3493026912776949,0.1579852685952437,0.995170154694874,0.9910673490027657,NLRP1/NOD1/CARD9/CASP4,4
R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,4/349,23/3769,0.17391304347826086,1.8781612059299864,1.3493026912776949,0.1579852685952437,0.995170154694874,0.9910673490027657,BCL6/TNFRSF10B/TNFRSF10D/TNFRSF10C,4
R-HSA-181431,Acetylcholine binding and downstream events,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,CHRNA4/CHRNA6,2
R-HSA-399954,Sema3A PAK dependent Axon repulsion,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,LIMK1/PLXNA1,2
R-HSA-5627117,RHO GTPases Activate ROCKs,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,LIMK1/LIMK2,2
R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,BAD/CDKN1A,2
R-HSA-622327,Postsynaptic nicotinic acetylcholine receptors,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,CHRNA4/CHRNA6,2
R-HSA-629594,Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,CHRNA4/CHRNA6,2
R-HSA-69615,G1/S DNA Damage Checkpoints,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,CDK2/CDKN1A,2
R-HSA-9013507,NOTCH3 Activation and Transmission of Signal to the Nucleus,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,JAG2/MIB2,2
R-HSA-936964,"Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)",2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,LY96/CD14,2
R-HSA-9823739,Formation of the anterior neural plate,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,ZIC2/OTX2,2
R-HSA-9824878,"Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7",2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,LY96/CD14,2
R-HSA-982772,Growth hormone receptor signaling,2/349,8/3769,0.25,2.6998567335243555,1.5373075292569434,0.16502101646982795,0.995170154694874,0.9910673490027657,CISH/SOCS3,2
R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,5/349,32/3769,0.15625,1.687410458452722,1.24733952164388,0.16907933671211892,0.995170154694874,0.9910673490027657,NOD1/TLR2/IFNA5/B2M/ISG15,5
R-HSA-421270,Cell-cell junction organization,6/349,41/3769,0.14634146341463414,1.5804039415752322,1.1935467571309317,0.17393283284232053,0.995170154694874,0.9910673490027657,SDK1/ADAM33/PRDM8/F11R/ANGPTL4/CDH5,6
R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,6/349,41/3769,0.14634146341463414,1.5804039415752322,1.1935467571309317,0.17393283284232053,0.995170154694874,0.9910673490027657,HCK/IL6/FCGR2A/FCGR1A/DPEP2/FCGR3A,6
R-HSA-9664433,Leishmania parasite growth and survival,6/349,41/3769,0.14634146341463414,1.5804039415752322,1.1935467571309317,0.17393283284232053,0.995170154694874,0.9910673490027657,HCK/IL6/FCGR2A/FCGR1A/DPEP2/FCGR3A,6
R-HSA-216083,Integrin cell surface interactions,8/349,59/3769,0.13559322033898305,1.4643290758098197,1.1482065979195082,0.17501434836161603,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/THBS1/F11R/COL8A2/COL4A1/ITGB3/PECAM1,8
R-HSA-8951664,Neddylation,7/349,50/3769,0.14,1.5119197707736391,1.163935523675646,0.17544752585421092,0.995170154694874,0.9910673490027657,CISH/CDKN1A/FBXW5/FBXO40/SPSB1/SPSB4/SOCS3,7
R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,9/349,69/3769,0.13043478260869565,1.4086209044474896,1.094206704733789,0.18426753919164082,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TLR2/S100A8/TIFA/LY96/S100A9/CD14/SFTPA2,9
R-HSA-5357801,Programmed Cell Death,9/349,69/3769,0.13043478260869565,1.4086209044474896,1.094206704733789,0.18426753919164082,0.995170154694874,0.9910673490027657,BAD/LMNB1/TNFRSF10B/TNFSF10/IRF1/IL1B/LY96/CD14/CASP4,9
R-HSA-388396,GPCR downstream signalling,35/349,327/3769,0.10703363914373089,1.1559019654232714,0.9422695158668395,0.19783926034038246,0.995170154694874,0.9910673490027657,TRPC7/EDN1/CXCL2/NTSR1/CALCA/POMC/RGS2/HCRTR1/EDN3/MCHR1/ARHGEF16/RAMP2/GPR45/HCRTR2/GPR84/ADCYAP1/RGS16/ADM/ADRA2A/GNA14/SHC1/CCR1/GRM2/BDKRB2/DRD5/TRH/FPR2/FPR1/P2RY6/GPR4/CXCR2/CCR10/QRFPR/C5AR1/SSTR3,35
R-HSA-140875,Common Pathway of Fibrin Clot Formation,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,F13A1/THBD,2
R-HSA-2142845,Hyaluronan metabolism,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,HAS1/HYAL3,2
R-HSA-6806003,Regulation of TP53 Expression and Degradation,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,PRDM1/CDK2,2
R-HSA-68949,Orc1 removal from chromatin,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,CDK2/CDT1,2
R-HSA-9635486,Infection with Mycobacterium tuberculosis,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,TLR2/B2M,2
R-HSA-9703465,Signaling by FLT3 fusion proteins,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,CDKN1A/PIM1,2
R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,CDKN1A/PIM1,2
R-HSA-9925561,Developmental Lineage of Pancreatic Acinar Cells,2/349,9/3769,0.2222222222222222,2.399872652021649,1.3429844031576736,0.1997846435960016,0.995170154694874,0.9910673490027657,CPB1/BHLHA15,2
R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,5/349,34/3769,0.14705882352941177,1.588151019720209,1.100368418506543,0.20187176295084944,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/LOXL4/COL8A2/COL4A1,5
R-HSA-9758941,Gastrulation,6/349,43/3769,0.13953488372093023,1.5068967815019658,1.0677939201823587,0.20299170627677623,0.995170154694874,0.9910673490027657,ZIC2/FGF2/NOTCH1/SOX17/OTX2/TEAD4,6
R-HSA-166520,Signaling by NTRKs,9/349,71/3769,0.1267605633802817,1.3689414423503772,1.0024397274192263,0.20691506290469883,0.995170154694874,0.9910673490027657,LYL1/F3/DUSP4/VGF/EGR4/ADCYAP1/SHC1/CRK/ARC,9
R-HSA-114608,Platelet degranulation,8/349,62/3769,0.12903225806451613,1.3934744431093447,0.9978291537112312,0.21140065864627935,0.995170154694874,0.9910673490027657,TIMP1/SRGN/F13A1/THBS1/SERPINA3/SERPINA1/ITGB3/PECAM1,8
R-HSA-1442490,Collagen degradation,5/349,35/3769,0.14285714285714285,1.5427752762996316,1.0304383890244484,0.21901777450089832,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/CTSD/COL8A2/COL4A1,5
R-HSA-375165,NCAM signaling for neurite out-growth,5/349,35/3769,0.14285714285714285,1.5427752762996316,1.0304383890244484,0.21901777450089832,0.995170154694874,0.9910673490027657,CACNA1G/COL5A3/COL9A3/SPTBN5/COL4A1,5
R-HSA-1592389,Activation of Matrix Metalloproteinases,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,TIMP1/MMP17,2
R-HSA-1614635,Sulfur amino acid metabolism,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,GADL1/SLC25A10,2
R-HSA-2022870,Chondroitin sulfate biosynthesis,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,CHST3/CHSY1,2
R-HSA-210993,Tie2 Signaling,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,ANGPT2/SHC1,2
R-HSA-2243919,Crosslinking of collagen fibrils,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,LOXL4/COL4A1,2
R-HSA-416572,Sema4D induced cell migration and growth-cone collapse,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,LIMK1/LIMK2,2
R-HSA-4641263,Regulation of FZD by ubiquitination,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,LGR6/FZD8,2
R-HSA-5423646,Aflatoxin activation and detoxification,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,DPEP2/ACY1,2
R-HSA-5654719,SHC-mediated cascade:FGFR4,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-9682385,FLT3 signaling in disease,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,CDKN1A/PIM1,2
R-HSA-9825892,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,CDK2/CDKN1A,2
R-HSA-9937080,Developmental Lineage of Multipotent Pancreatic Progenitor Cells,2/349,10/3769,0.2,2.1598853868194845,1.173097263016883,0.23528445524609057,0.995170154694874,0.9910673490027657,FGF2/SOX17,2
R-HSA-211859,Biological oxidations,10/349,83/3769,0.12048192771084337,1.3011357751924604,0.8860920526645543,0.23546275247963394,0.995170154694874,0.9910673490027657,CYP3A43/POMC/CHAC1/CYP1B1/SLC26A1/GLYATL1/DPEP2/OPLAH/CYP26C1/ACY1,10
R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,4/349,27/3769,0.14814814814814814,1.599915101347766,0.9992516920968094,0.2364616947228791,0.995170154694874,0.9910673490027657,CEP131/PLK4/MZT2B/TUBB6,4
R-HSA-418990,Adherens junctions interactions,4/349,27/3769,0.14814814814814814,1.599915101347766,0.9992516920968094,0.2364616947228791,0.995170154694874,0.9910673490027657,ADAM33/PRDM8/ANGPTL4/CDH5,4
R-HSA-9752946,Expression and translocation of olfactory receptors,4/349,27/3769,0.14814814814814814,1.599915101347766,0.9992516920968094,0.2364616947228791,0.995170154694874,0.9910673490027657,OR2AT4/RTP1/OR51E1/OR8A1,4
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,8/349,64/3769,0.125,1.3499283667621778,0.901841337557898,0.23715572300255122,0.995170154694874,0.9910673490027657,TIMP1/SRGN/F13A1/THBS1/SERPINA3/SERPINA1/ITGB3/PECAM1,8
R-HSA-8957275,Post-translational protein phosphorylation,7/349,55/3769,0.12727272727272726,1.3744725188851261,0.8935841452430436,0.24354198005937433,0.995170154694874,0.9910673490027657,TMEM132A/CP/TIMP1/VGF/IL6/MELTF/SERPINA1,7
R-HSA-193704,p75 NTR receptor-mediated signalling,5/349,37/3769,0.13513513513513514,1.4593820181212733,0.8969312247975549,0.25454260996197325,0.995170154694874,0.9910673490027657,BAD/RTN4R/NGFR/ARHGEF16/LINGO1,5
R-HSA-352230,Amino acid transport across the plasma membrane,3/349,19/3769,0.15789473684210525,1.7051726738048558,0.9842643351184263,0.25485362751550494,0.995170154694874,0.9910673490027657,SLC7A2/SLC38A5/SLC1A5,3
R-HSA-3928662,EPHB-mediated forward signaling,3/349,19/3769,0.15789473684210525,1.7051726738048558,0.9842643351184263,0.25485362751550494,0.995170154694874,0.9910673490027657,LIMK1/LIMK2/EPHB3,3
R-HSA-5362517,Signaling by Retinoic Acid,3/349,19/3769,0.15789473684210525,1.7051726738048558,0.9842643351184263,0.25485362751550494,0.995170154694874,0.9910673490027657,DHRS9/PDK1/CYP26C1,3
R-HSA-211897,Cytochrome P450 - arranged by substrate type,4/349,28/3769,0.14285714285714285,1.5427752762996316,0.9207894319442725,0.25739146458107554,0.995170154694874,0.9910673490027657,CYP3A43/POMC/CYP1B1/CYP26C1,4
R-HSA-419037,NCAM1 interactions,4/349,28/3769,0.14285714285714285,1.5427752762996316,0.9207894319442725,0.25739146458107554,0.995170154694874,0.9910673490027657,CACNA1G/COL5A3/COL9A3/COL4A1,4
R-HSA-1474165,Reproduction,7/349,56/3769,0.125,1.3499283667621778,0.842686033681554,0.25808391136199105,0.995170154694874,0.9910673490027657,PRDM1/OVGP1/LMNB1/CDK2/PDPN/SOX17/H3C2,7
R-HSA-211976,Endogenous sterols,2/349,11/3769,0.18181818181818182,1.9635321698358947,1.0222080138883738,0.27108752265471137,0.995170154694874,0.9910673490027657,POMC/CYP1B1,2
R-HSA-3000480,Scavenging by Class A Receptors,2/349,11/3769,0.18181818181818182,1.9635321698358947,1.0222080138883738,0.27108752265471137,0.995170154694874,0.9910673490027657,MSR1/COL4A1,2
R-HSA-5365859,RA biosynthesis pathway,2/349,11/3769,0.18181818181818182,1.9635321698358947,1.0222080138883738,0.27108752265471137,0.995170154694874,0.9910673490027657,DHRS9/CYP26C1,2
R-HSA-5654704,SHC-mediated cascade:FGFR3,2/349,11/3769,0.18181818181818182,1.9635321698358947,1.0222080138883738,0.27108752265471137,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-69052,Switching of origins to a post-replicative state,2/349,11/3769,0.18181818181818182,1.9635321698358947,1.0222080138883738,0.27108752265471137,0.995170154694874,0.9910673490027657,CDK2/CDT1,2
R-HSA-8849932,Synaptic adhesion-like molecules,2/349,11/3769,0.18181818181818182,1.9635321698358947,1.0222080138883738,0.27108752265471137,0.995170154694874,0.9910673490027657,LRFN1/LRFN4,2
R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,2/349,11/3769,0.18181818181818182,1.9635321698358947,1.0222080138883738,0.27108752265471137,0.995170154694874,0.9910673490027657,HCK/SHC1,2
R-HSA-2980736,Peptide hormone metabolism,5/349,38/3769,0.13157894736842105,1.4209772281707131,0.8330918494530489,0.272813112761195,0.995170154694874,0.9910673490027657,ACHE/POMC/CTSD/CPB1/INHBB,5
R-HSA-425366,"Transport of bile salts and organic acids, metal ions and amine compounds",5/349,38/3769,0.13157894736842105,1.4209772281707131,0.8330918494530489,0.272813112761195,0.995170154694874,0.9910673490027657,SLC11A1/CP/SLC39A14/RUNX1/SLC13A4,5
R-HSA-4086400,PCP/CE pathway,4/349,29/3769,0.13793103448275862,1.4895761288410234,0.8453538585956195,0.2786710150357793,0.995170154694874,0.9910673490027657,RAC2/RAC3/FZD8/SCRIB,4
R-HSA-9658195,Leishmania infection,9/349,77/3769,0.11688311688311688,1.2622706806087896,0.7427101638472087,0.28077887089471704,0.995170154694874,0.9910673490027657,HCK/IL1B/IL6/FCGR2A/FCGR1A/CRK/DPEP2/NOXA1/FCGR3A,9
R-HSA-9824443,Parasitic Infection Pathways,9/349,77/3769,0.11688311688311688,1.2622706806087896,0.7427101638472087,0.28077887089471704,0.995170154694874,0.9910673490027657,HCK/IL1B/IL6/FCGR2A/FCGR1A/CRK/DPEP2/NOXA1/FCGR3A,9
R-HSA-9664407,Parasite infection,3/349,20/3769,0.15,1.6199140401146133,0.8878587062783136,0.2809322388538779,0.995170154694874,0.9910673490027657,HCK/CRK/FCGR3A,3
R-HSA-9664417,Leishmania phagocytosis,3/349,20/3769,0.15,1.6199140401146133,0.8878587062783136,0.2809322388538779,0.995170154694874,0.9910673490027657,HCK/CRK/FCGR3A,3
R-HSA-9664422,FCGR3A-mediated phagocytosis,3/349,20/3769,0.15,1.6199140401146133,0.8878587062783136,0.2809322388538779,0.995170154694874,0.9910673490027657,HCK/CRK/FCGR3A,3
R-HSA-1474244,Extracellular matrix organization,18/349,167/3769,0.10778443113772455,1.1640100887051112,0.692487681661028,0.2812083593067583,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/TIMP1/CAPN15/CTSD/TTR/THBS1/LOXL4/FGF2/PLOD2/F11R/SCUBE1/ADAMTS9/COL8A2/COL4A1/MMP17/ITGB3/PECAM1,18
R-HSA-1474290,Collagen formation,6/349,48/3769,0.125,1.3499283667621778,0.7793365433986711,0.2820734929509771,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/LOXL4/PLOD2/COL8A2/COL4A1,6
R-HSA-3000171,Non-integrin membrane-ECM interactions,6/349,48/3769,0.125,1.3499283667621778,0.7793365433986711,0.2820734929509771,0.995170154694874,0.9910673490027657,COL5A3/TTR/THBS1/FGF2/COL4A1/ITGB3,6
R-HSA-446652,Interleukin-1 family signaling,6/349,48/3769,0.125,1.3499283667621778,0.7793365433986711,0.2820734929509771,0.995170154694874,0.9910673490027657,NOD1/IL1R1/IL1RL1/IL18RAP/IL1B/TIFA,6
R-HSA-1650814,Collagen biosynthesis and modifying enzymes,5/349,39/3769,0.1282051282051282,1.3845419146278743,0.7710395925170639,0.2913503550497838,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/PLOD2/COL8A2/COL4A1,5
R-HSA-983231,Factors involved in megakaryocyte development and platelet production,8/349,68/3769,0.11764705882352941,1.2705208157761672,0.719036124102002,0.29153525556868537,0.995170154694874,0.9910673490027657,KIF26A/CDK2/IRF1/IFNA5/SH2B2/TUBB6/MAFF/H3C2,8
R-HSA-418555,G alpha (s) signalling events,9/349,78/3769,0.11538461538461539,1.246087723165087,0.7014881425101024,0.29378116036089624,0.995170154694874,0.9910673490027657,CALCA/POMC/RAMP2/GPR45/GPR84/ADCYAP1/ADM/SHC1/DRD5,9
R-HSA-1483191,Synthesis of PC,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,ACHE/LPCAT1,2
R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,HCK/B2M,2
R-HSA-1980145,Signaling by NOTCH2,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,JAG2/MIB2,2
R-HSA-400685,Sema4D in semaphorin signaling,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,LIMK1/LIMK2,2
R-HSA-418360,Platelet calcium homeostasis,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,TRPC7/ATP2A3,2
R-HSA-499943,Interconversion of nucleotide di- and triphosphates,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,NME3/GLRX,2
R-HSA-5654688,SHC-mediated cascade:FGFR1,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-5654699,SHC-mediated cascade:FGFR2,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-68962,Activation of the pre-replicative complex,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,CDK2/CDT1,2
R-HSA-69231,Cyclin D associated events in G1,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,CDK2/CDKN1A,2
R-HSA-69236,G1 Phase,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,CDK2/CDKN1A,2
R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,2/349,12/3769,0.16666666666666666,1.7999044890162368,0.8864684166283733,0.30683437981913,0.995170154694874,0.9910673490027657,IRF4/BCL2A1,2
R-HSA-8948216,Collagen chain trimerization,4/349,31/3769,0.12903225806451613,1.3934744431093447,0.702639944259352,0.32194692140760395,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/COL8A2/COL4A1,4
R-HSA-9020702,Interleukin-1 signaling,4/349,31/3769,0.12903225806451613,1.3934744431093447,0.702639944259352,0.32194692140760395,0.995170154694874,0.9910673490027657,NOD1/IL1R1/IL1B/TIFA,4
R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,NOTCH1/JAG2/MIB2,3
R-HSA-2644603,Signaling by NOTCH1 in Cancer,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,NOTCH1/JAG2/MIB2,3
R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,NOTCH1/JAG2/MIB2,3
R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,NOTCH1/JAG2/MIB2,3
R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,NOTCH1/JAG2/MIB2,3
R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,CEP131/PLK4/MZT2B,3
R-HSA-380287,Centrosome maturation,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,CEP131/PLK4/MZT2B,3
R-HSA-9012852,Signaling by NOTCH3,3/349,22/3769,0.13636363636363635,1.4726491273769209,0.7101718633770897,0.3336211509745276,0.995170154694874,0.9910673490027657,NOTCH1/JAG2/MIB2,3
R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),7/349,61/3769,0.11475409836065574,1.2392785006341303,0.6018022968430817,0.33390726353641176,0.995170154694874,0.9910673490027657,TMEM132A/CP/TIMP1/VGF/IL6/MELTF/SERPINA1,7
R-HSA-450531,Regulation of mRNA stability by proteins that bind AU-rich elements,2/349,13/3769,0.15384615384615385,1.6614502975534498,0.7630644273588005,0.3422291918105157,0.995170154694874,0.9910673490027657,ZFP36/PARN,2
R-HSA-4608870,Asymmetric localization of PCP proteins,2/349,13/3769,0.15384615384615385,1.6614502975534498,0.7630644273588005,0.3422291918105157,0.995170154694874,0.9910673490027657,FZD8/SCRIB,2
R-HSA-5213460,RIPK1-mediated regulated necrosis,2/349,13/3769,0.15384615384615385,1.6614502975534498,0.7630644273588005,0.3422291918105157,0.995170154694874,0.9910673490027657,TNFRSF10B/TNFSF10,2
R-HSA-5654716,Downstream signaling of activated FGFR4,2/349,13/3769,0.15384615384615385,1.6614502975534498,0.7630644273588005,0.3422291918105157,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-5675482,Regulation of necroptotic cell death,2/349,13/3769,0.15384615384615385,1.6614502975534498,0.7630644273588005,0.3422291918105157,0.995170154694874,0.9910673490027657,TNFRSF10B/TNFSF10,2
R-HSA-70268,Pyruvate metabolism,2/349,13/3769,0.15384615384615385,1.6614502975534498,0.7630644273588005,0.3422291918105157,0.995170154694874,0.9910673490027657,PDK1/GPT,2
R-HSA-9820960,Respiratory syncytial virus (RSV) attachment and entry,2/349,13/3769,0.15384615384615385,1.6614502975534498,0.7630644273588005,0.3422291918105157,0.995170154694874,0.9910673490027657,LY96/CD14,2
R-HSA-5684996,MAPK1/MAPK3 signaling,11/349,102/3769,0.10784313725490197,1.1646440811281533,0.5384505948392169,0.3432211179981978,0.995170154694874,0.9910673490027657,CSF2RB/RASAL3/JAK3/DUSP4/IL6/SPTBN5/DUSP5/FGF2/DUSP2/SHC1/ITGB3,11
R-HSA-168898,Toll-like Receptor Cascades,9/349,82/3769,0.10975609756097561,1.1853029561814243,0.541885852539417,0.34712556317938975,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TLR2/S100A8/TIFA/LY96/S100A9/CD14/SFTPA2,9
R-HSA-977225,Amyloid fiber formation,5/349,42/3769,0.11904761904761904,1.2856460635830262,0.59460464816962,0.3480364735888163,0.995170154694874,0.9910673490027657,LYZ/CALCA/TTR/B2M/H3C2,5
R-HSA-5083635,Defective B3GALTL causes PpS,3/349,23/3769,0.13043478260869565,1.4086209044474896,0.6278497414372023,0.3599665333314196,0.995170154694874,0.9910673490027657,THBS1/ADAMTS9/ADAMTSL2,3
R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,3/349,23/3769,0.13043478260869565,1.4086209044474896,0.6278497414372023,0.3599665333314196,0.995170154694874,0.9910673490027657,THBS1/ADAMTS9/ADAMTSL2,3
R-HSA-8873719,RAB geranylgeranylation,3/349,23/3769,0.13043478260869565,1.4086209044474896,0.6278497414372023,0.3599665333314196,0.995170154694874,0.9910673490027657,RAB20/RAB24/RAB43,3
R-HSA-9730414,MITF-M-regulated melanocyte development,7/349,63/3769,0.1111111111111111,1.1999363260108244,0.5111688517655167,0.36516872471586415,0.995170154694874,0.9910673490027657,EDN1/POMC/CDK2/EDN3/CDKN1A/IRF4/BCL2A1,7
R-HSA-381753,Olfactory Signaling Pathway,4/349,33/3769,0.12121212121212122,1.3090214465572632,0.5695046374095852,0.36565783236116356,0.995170154694874,0.9910673490027657,OR2AT4/RTP1/OR51E1/OR8A1,4
R-HSA-156590,Glutathione conjugation,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,CHAC1/OPLAH,2
R-HSA-2424491,DAP12 signaling,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,SHC1/B2M,2
R-HSA-2453902,The canonical retinoid cycle in rods (twilight vision),2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,DHRS9/TTR,2
R-HSA-264642,Acetylcholine Neurotransmitter Release Cycle,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,CPLX1/SLC18A3,2
R-HSA-445989,TAK1-dependent IKK and NF-kappa-B activation,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,NOD1/TIFA,2
R-HSA-5654708,Downstream signaling of activated FGFR3,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-6807505,RNA polymerase II transcribes snRNA genes,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,ELL2/NABP1,2
R-HSA-69202,Cyclin E associated events during G1/S transition,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,CDK2/CDKN1A,2
R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,CDKN1A/CITED2,2
R-HSA-9839373,Signaling by TGFBR3,2/349,14/3769,0.14285714285714285,1.5427752762996316,0.6498815562293249,0.37703110614807,0.995170154694874,0.9910673490027657,TIMP1/FGF2,2
R-HSA-453274,Mitotic G2-G2/M phases,6/349,54/3769,0.1111111111111111,1.1999363260108244,0.4726767989122634,0.38382440306695476,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/CEP131/PLK4/MZT2B/TUBB6,6
R-HSA-69275,G2/M Transition,6/349,54/3769,0.1111111111111111,1.1999363260108244,0.4726767989122634,0.38382440306695476,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/CEP131/PLK4/MZT2B/TUBB6,6
R-HSA-1433617,Regulation of signaling by NODAL,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,CRIPTO,1
R-HSA-156587,Amino Acid conjugation,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,GLYATL1,1
R-HSA-159424,Conjugation of carboxylic acids,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,GLYATL1,1
R-HSA-187015,Activation of TRKA receptors,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,ADCYAP1,1
R-HSA-190377,FGFR2b ligand binding and activation,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-2024101,CS/DS degradation,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,HYAL3,1
R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,PTPN22,1
R-HSA-209968,Thyroxine biosynthesis,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,DUOX1,1
R-HSA-211958,Miscellaneous substrates,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,CYP3A43,1
R-HSA-2160916,Hyaluronan uptake and degradation,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,HYAL3,1
R-HSA-2559584,Formation of Senescence-Associated Heterochromatin Foci (SAHF),1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-354194,GRB2:SOS provides linkage to MAPK signaling for Integrins,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-399997,Acetylcholine regulates insulin secretion,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-427601,Multifunctional anion exchangers,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,SLC26A1,1
R-HSA-429947,Deadenylation of mRNA,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,PARN,1
R-HSA-434316,Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-447041,CHL1 interactions,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,CNTN6,1
R-HSA-549127,Organic cation transport,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-5656169,Termination of translesion DNA synthesis,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,ISG15,1
R-HSA-6782315,tRNA modification in the nucleus and cytosol,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,ADAT3,1
R-HSA-75892,Platelet Adhesion to exposed collagen,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,FCER1G,1
R-HSA-877312,Regulation of IFNG signaling,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,SOCS3,1
R-HSA-8851708,Signaling by FGFR2 IIIa TM,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-8866907,Activation of the TFAP2 (AP-2) family of transcription factors,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,CITED2,1
R-HSA-8934593,Regulation of RUNX1 Expression and Activity,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-8941855,RUNX3 regulates CDKN1A transcription,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,CDKN1A,1
R-HSA-9027284,Erythropoietin activates RAS,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-917729,Endosomal Sorting Complex Required For Transport (ESCRT),1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,VPS28,1
R-HSA-9762293,Regulation of CDH11 gene transcription,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,PRDM8,1
R-HSA-9796292,Formation of axial mesoderm,1/349,5/3769,0.2,2.1598853868194845,0.8289539000970041,0.38499002740857735,0.995170154694874,0.9910673490027657,TEAD4,1
R-HSA-8848021,Signaling by PTK6,3/349,24/3769,0.125,1.3499283667621778,0.5493055248396203,0.3861558514651624,0.995170154694874,0.9910673490027657,CDK2/CRK/SOCS3,3
R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,3/349,24/3769,0.125,1.3499283667621778,0.5493055248396203,0.3861558514651624,0.995170154694874,0.9910673490027657,CDK2/CRK/SOCS3,3
R-HSA-9860931,Response of endothelial cells to shear stress,5/349,44/3769,0.11363636363636363,1.2272076061474342,0.48421827164025066,0.38622085873544865,0.995170154694874,0.9910673490027657,RAMP2/ADM/CDH5/ITGB3/PECAM1,5
R-HSA-3906995,Diseases associated with O-glycosylation of proteins,4/349,34/3769,0.11764705882352941,1.2705208157761672,0.5061158652251043,0.3874959749492053,0.995170154694874,0.9910673490027657,THBS1/NOTCH1/ADAMTS9/ADAMTSL2,4
R-HSA-9856530,High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,4/349,34/3769,0.11764705882352941,1.2705208157761672,0.5061158652251043,0.3874959749492053,0.995170154694874,0.9910673490027657,RAMP2/ADM/CDH5/PECAM1,4
R-HSA-5683057,MAPK family signaling cascades,12/349,116/3769,0.10344827586206896,1.1171820966307677,0.40946853077974565,0.3875556619156041,0.995170154694874,0.9910673490027657,CSF2RB/RASAL3/JAK3/DUSP4/IL6/SPTBN5/DUSP5/FGF2/DUSP2/SHC1/RAG1/ITGB3,12
R-HSA-446728,Cell junction organization,6/349,55/3769,0.10909090909090909,1.1781193019015368,0.42503675467250496,0.40100184261890326,0.995170154694874,0.9910673490027657,SDK1/ADAM33/PRDM8/F11R/ANGPTL4/CDH5,6
R-HSA-166166,MyD88-independent TLR4 cascade,5/349,45/3769,0.1111111111111111,1.1999363260108244,0.430971186637303,0.40529015444583283,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA/LY96/CD14,5
R-HSA-937061,TRIF (TICAM1)-mediated TLR4 signaling,5/349,45/3769,0.1111111111111111,1.1999363260108244,0.430971186637303,0.40529015444583283,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA/LY96/CD14,5
R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,5/349,45/3769,0.1111111111111111,1.1999363260108244,0.430971186637303,0.40529015444583283,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA/LY96/CD14,5
R-HSA-975155,MyD88 dependent cascade initiated on endosome,5/349,45/3769,0.1111111111111111,1.1999363260108244,0.430971186637303,0.40529015444583283,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA/LY96/CD14,5
R-HSA-8878159,Transcriptional regulation by RUNX3,4/349,35/3769,0.11428571428571428,1.2342202210397053,0.44465825505263157,0.4092350975876963,0.995170154694874,0.9910673490027657,CDKN1A/NOTCH1/RUNX1/TEAD4,4
R-HSA-9700206,Signaling by ALK in cancer,4/349,35/3769,0.11428571428571428,1.2342202210397053,0.44465825505263157,0.4092350975876963,0.995170154694874,0.9910673490027657,CDKN1A/IRF4/BCL2A1/SHC1,4
R-HSA-9725370,Signaling by ALK fusions and activated point mutants,4/349,35/3769,0.11428571428571428,1.2342202210397053,0.44465825505263157,0.4092350975876963,0.995170154694874,0.9910673490027657,CDKN1A/IRF4/BCL2A1/SHC1,4
R-HSA-187687,Signalling to ERKs,2/349,15/3769,0.13333333333333333,1.4399235912129895,0.5452941704824588,0.4110466533543261,0.995170154694874,0.9910673490027657,SHC1/CRK,2
R-HSA-5654696,Downstream signaling of activated FGFR2,2/349,15/3769,0.13333333333333333,1.4399235912129895,0.5452941704824588,0.4110466533543261,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,3/349,25/3769,0.12,1.2959312320916905,0.4741851991416983,0.41208642333162915,0.995170154694874,0.9910673490027657,CHST3/CHSY1/HYAL3,3
R-HSA-109581,Apoptosis,6/349,56/3769,0.10714285714285714,1.1570814572247237,0.37827842131925304,0.4181519943697328,0.995170154694874,0.9910673490027657,BAD/LMNB1/TNFRSF10B/TNFSF10/LY96/CD14,6
R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,5/349,46/3769,0.10869565217391304,1.1738507537062415,0.37893444396634035,0.42428651213589463,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA/LY96/CD14,5
R-HSA-156580,Phase II - Conjugation of compounds,4/349,36/3769,0.1111111111111111,1.1999363260108244,0.38500739411754104,0.4308153904352179,0.995170154694874,0.9910673490027657,CHAC1/SLC26A1/GLYATL1/OPLAH,4
R-HSA-5621481,C-type lectin receptors (CLRs),4/349,36/3769,0.1111111111111111,1.1999363260108244,0.38500739411754104,0.4308153904352179,0.995170154694874,0.9910673490027657,CD209/IL1B/FCER1G/CARD9,4
R-HSA-3781865,Diseases of glycosylation,6/349,57/3769,0.10526315789473684,1.1367817825365705,0.33236616859797863,0.4352439111560983,0.995170154694874,0.9910673490027657,CHST3/CHSY1/THBS1/NOTCH1/ADAMTS9/ADAMTSL2,6
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,3/349,26/3769,0.11538461538461539,1.246087723165087,0.4021812467518913,0.4376670866544685,0.995170154694874,0.9910673490027657,EDN1/POMC/EDN3,3
R-HSA-418594,G alpha (i) signalling events,15/349,152/3769,0.09868421052631579,1.065732921128035,0.26423210195660096,0.4377508757399252,0.995170154694874,0.9910673490027657,CXCL2/POMC/MCHR1/RGS16/ADRA2A/GNA14/CCR1/GRM2/BDKRB2/FPR2/FPR1/CXCR2/CCR10/C5AR1/SSTR3,15
R-HSA-1643685,Disease,59/349,622/3769,0.09485530546623794,1.0243829406941285,0.21256316636099512,0.44022869325264463,0.995170154694874,0.9910673490027657,BAD/ABCB4/CP/MBD3/CD209/BLNK/CSF2RB/HCK/JAK3/NOD1/LMNB1/POMC/IL1R1/TTR/CHST3/CDK2/CDKN1A/IL1B/RAC2/CHSY1/IL6/PIM1/IRF4/TLR2/THBS1/CYP1B1/FGF2/BCL2A1/FCGR2A/S100A8/IFNA5/NOTCH1/FCGR1A/LY96/RUNX1/SHC1/VPS28/S100A9/ADAMTS9/B2M/CRK/DPEP2/CD14/TUBB6/FZD8/OPLAH/JAG2/SFTPA2/CYP26C1/ISG15/NOXA1/MIB2/ADAMTSL2/PNP/FCGR3A/ACY1/BCKDHA/ITGB3/H3C2,59
R-HSA-110313,Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,ISG15,1
R-HSA-1236978,Cross-presentation of soluble exogenous antigens (endosomes),1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,FCGR1A,1
R-HSA-139853,Elevation of cytosolic Ca2+ levels,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,TRPC7,1
R-HSA-1433559,Regulation of KIT signaling,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,SH2B2,1
R-HSA-169893,Prolonged ERK activation events,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,CRK,1
R-HSA-1839122,Signaling by activated point mutants of FGFR1,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-200425,Carnitine shuttle,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,THRSP,1
R-HSA-204174,Regulation of pyruvate dehydrogenase (PDH) complex,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,PDK1,1
R-HSA-2142691,Synthesis of Leukotrienes (LT) and Eoxins (EX),1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,DPEP2,1
R-HSA-2173791,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,F11R,1
R-HSA-390471,Association of TriC/CCT with target proteins during biosynthesis,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,FBXW5,1
R-HSA-390696,Adrenoceptors,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,ADRA2A,1
R-HSA-399955,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,PLXNA1,1
R-HSA-418359,Reduction of cytosolic Ca++ levels,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,ATP2A3,1
R-HSA-429914,Deadenylation-dependent mRNA decay,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,PARN,1
R-HSA-435354,Zinc transporters,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,SLC39A14,1
R-HSA-448706,Interleukin-1 processing,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,IL1B,1
R-HSA-451306,Ionotropic activity of kainate receptors,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,NCALD,1
R-HSA-451308,Activation of Ca-permeable Kainate Receptor,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,NCALD,1
R-HSA-5694530,Cargo concentration in the ER,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,SERPINA1,1
R-HSA-69017,CDK-mediated phosphorylation and removal of Cdc6,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-73762,RNA Polymerase I Transcription Initiation,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,MBD3,1
R-HSA-73893,DNA Damage Bypass,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,ISG15,1
R-HSA-74217,Purine salvage,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,PNP,1
R-HSA-8851805,MET activates RAS signaling,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-8854691,Interleukin-20 family signaling,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,JAK3,1
R-HSA-8949613,Cristae formation,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,ATP5F1D,1
R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,TEAD4,1
R-HSA-8951936,RUNX3 regulates p14-ARF,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-9634285,Constitutive Signaling by Overexpressed ERBB2,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9733709,Cardiogenesis,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,MESP1,1
R-HSA-9755088,Ribavirin ADME,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,PNP,1
R-HSA-9842663,Signaling by LTK,1/349,6/3769,0.16666666666666666,1.7999044890162368,0.6263278994791784,0.4420140657811612,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,5/349,47/3769,0.10638297872340426,1.1488752057550449,0.3280486287946622,0.4431696444101555,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA/LY96/CD14,5
R-HSA-9820448,Developmental Cell Lineages of the Exocrine Pancreas,5/349,47/3769,0.10638297872340426,1.1488752057550449,0.3280486287946622,0.4431696444101555,0.995170154694874,0.9910673490027657,COL5A3/FGF2/CPB1/SOX17/BHLHA15,5
R-HSA-1855204,Synthesis of IP3 and IP4 in the cytosol,2/349,16/3769,0.125,1.3499283667621778,0.4480278038328248,0.4441230773587349,0.995170154694874,0.9910673490027657,ITPKC/PLD4,2
R-HSA-202040,G-protein activation,2/349,16/3769,0.125,1.3499283667621778,0.4480278038328248,0.4441230773587349,0.995170154694874,0.9910673490027657,POMC/GNA14,2
R-HSA-2871809,FCERI mediated Ca+2 mobilization,2/349,16/3769,0.125,1.3499283667621778,0.4480278038328248,0.4441230773587349,0.995170154694874,0.9910673490027657,FCER1G/SHC1,2
R-HSA-5620920,Cargo trafficking to the periciliary membrane,2/349,16/3769,0.125,1.3499283667621778,0.4480278038328248,0.4441230773587349,0.995170154694874,0.9910673490027657,MCHR1/SSTR3,2
R-HSA-5654743,Signaling by FGFR4,2/349,16/3769,0.125,1.3499283667621778,0.4480278038328248,0.4441230773587349,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-69656,Cyclin A:Cdk2-associated events at S phase entry,2/349,16/3769,0.125,1.3499283667621778,0.4480278038328248,0.4441230773587349,0.995170154694874,0.9910673490027657,CDK2/CDKN1A,2
R-HSA-9837999,Mitochondrial protein degradation,2/349,16/3769,0.125,1.3499283667621778,0.4480278038328248,0.4441230773587349,0.995170154694874,0.9910673490027657,PDK1/MRPL12,2
R-HSA-5673001,RAF/MAP kinase cascade,10/349,100/3769,0.1,1.0799426934097422,0.25879747094569927,0.4486753108032995,0.995170154694874,0.9910673490027657,CSF2RB/RASAL3/JAK3/DUSP4/SPTBN5/DUSP5/FGF2/DUSP2/SHC1/ITGB3,10
R-HSA-9616222,Transcriptional regulation of granulopoiesis,4/349,37/3769,0.10810810810810811,1.1675056144970186,0.3270502763380161,0.4521817880683383,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/RUNX1/H3C2,4
R-HSA-9679191,Potential therapeutics for SARS,4/349,37/3769,0.10810810810810811,1.1675056144970186,0.3270502763380161,0.4521817880683383,0.995170154694874,0.9910673490027657,MBD3/BLNK/JAK3/IL1R1,4
R-HSA-2142753,Arachidonate metabolism,3/349,27/3769,0.1111111111111111,1.1999363260108244,0.33302497574922857,0.46281776064591684,0.995170154694874,0.9910673490027657,CYP1B1/PTGES/DPEP2,3
R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,3/349,27/3769,0.1111111111111111,1.1999363260108244,0.33302497574922857,0.46281776064591684,0.995170154694874,0.9910673490027657,LMNB1/CDK2/CDKN1A,3
R-HSA-9013405,RHOD GTPase cycle,3/349,27/3769,0.1111111111111111,1.1999363260108244,0.33302497574922857,0.46281776064591684,0.995170154694874,0.9910673490027657,LMNB1/PLXNA1/HINT2,3
R-HSA-9755511,KEAP1-NFE2L2 pathway,3/349,27/3769,0.1111111111111111,1.1999363260108244,0.33302497574922857,0.46281776064591684,0.995170154694874,0.9910673490027657,CCL2/CDKN1A/NOTCH1,3
R-HSA-3700989,Transcriptional Regulation by TP53,9/349,91/3769,0.0989010989010989,1.0680751912843602,0.20997075582821972,0.4701645579001369,0.995170154694874,0.9910673490027657,PRDM1/MBD3/BCL6/GADD45A/TNFRSF10B/CDK2/CDKN1A/TNFRSF10D/TNFRSF10C,9
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),4/349,38/3769,0.10526315789473684,1.1367817825365705,0.2706839718624093,0.47328398516329606,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/IL6/H3C2,4
R-HSA-5654741,Signaling by FGFR3,2/349,17/3769,0.11764705882352941,1.2705208157761672,0.3570662822720462,0.47614248942986503,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,2/349,17/3769,0.11764705882352941,1.2705208157761672,0.3570662822720462,0.47614248942986503,0.995170154694874,0.9910673490027657,CDKN1A/TUBB6,2
R-HSA-1980143,Signaling by NOTCH1,3/349,28/3769,0.10714285714285714,1.1570814572247237,0.26648035030815587,0.48746891617369814,0.995170154694874,0.9910673490027657,NOTCH1/JAG2/MIB2,3
R-HSA-1500931,Cell-Cell communication,7/349,71/3769,0.09859154929577464,1.0647322329391822,0.17588200861741832,0.4902709015571727,0.995170154694874,0.9910673490027657,SDK1/ADAM33/PRDM8/F11R/ANGPTL4/CDH5/SFTPA2,7
R-HSA-111447,Activation of BAD and translocation to mitochondria,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,BAD,1
R-HSA-1296346,Tandem pore domain potassium channels,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,KCNK9,1
R-HSA-1482925,Acyl chain remodelling of PG,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,LPCAT1,1
R-HSA-1502540,Signaling by Activin,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,INHBB,1
R-HSA-166786,Creation of C4 and C2 activators,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,C1R,1
R-HSA-190322,FGFR4 ligand binding and activation,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-190373,FGFR1c ligand binding and activation,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-190375,FGFR2c ligand binding and activation,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-202131,Metabolism of nitric oxide: NOS3 activation and regulation,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,CYGB,1
R-HSA-203615,eNOS activation,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,CYGB,1
R-HSA-2995383,Initiation of Nuclear Envelope (NE) Reformation,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-389957,Prefoldin mediated transfer of substrate  to CCT/TriC,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-389960,Formation of tubulin folding intermediates by CCT/TriC,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-417957,P2Y receptors,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,P2RY6,1
R-HSA-419408,Lysosphingolipid and LPA receptors,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,PLPPR3,1
R-HSA-420499,Class C/3 (Metabotropic glutamate/pheromone receptors),1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,GRM2,1
R-HSA-432142,Platelet sensitization by LDL,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,PECAM1,1
R-HSA-4419969,Depolymerization of the Nuclear Lamina,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-450302,activated TAK1 mediates p38 MAPK activation,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,NOD1,1
R-HSA-5621575,CD209 (DC-SIGN) signaling,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,CD209,1
R-HSA-5654228,Phospholipase C-mediated cascade; FGFR4,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5658623,FGFRL1 modulation of FGFR1 signaling,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-6803205,TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,BCL6,1
R-HSA-6811440,Retrograde transport at the Trans-Golgi-Network,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,RAB43,1
R-HSA-70221,Glycogen breakdown (glycogenolysis),1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,PYGL,1
R-HSA-8851680,Butyrophilin (BTN) family interactions,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,CD209,1
R-HSA-8853884,Transcriptional Regulation by VENTX,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,IL6,1
R-HSA-8862803,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-8863678,Neurodegenerative Diseases,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-9648895,Response of EIF2AK1 (HRI) to heme deficiency,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,CHAC1,1
R-HSA-9664420,Killing mechanisms,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,NOXA1,1
R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,NOXA1,1
R-HSA-9832991,Formation of the posterior neural plate,1/349,7/3769,0.14285714285714285,1.5427752762996316,0.4591079244710085,0.49376455502973315,0.995170154694874,0.9910673490027657,OTX2,1
R-HSA-8953897,Cellular responses to stimuli,26/349,276/3769,0.09420289855072464,1.0173373198787425,0.0955635595226251,0.49486633784719714,0.995170154694874,0.9910673490027657,SNCB/FKBP5/CCL2/LMNB1/CDK2/CDKN1A/MT2A/CHAC1/RAMP2/HSPA12B/IL6/PARN/NOTCH1/ADM/LY96/CREB3L1/SHC1/CITED2/TUBB6/CDH5/MT1X/MT1A/MT1M/ITGB3/PECAM1/H3C2,26
R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,2/349,18/3769,0.1111111111111111,1.1999363260108244,0.2715873486384848,0.507016750952676,0.995170154694874,0.9910673490027657,MSR1/COL4A1,2
R-HSA-2871796,FCERI mediated MAPK activation,2/349,18/3769,0.1111111111111111,1.1999363260108244,0.2715873486384848,0.507016750952676,0.995170154694874,0.9910673490027657,FCER1G/SHC1,2
R-HSA-380259,Loss of Nlp from mitotic centrosomes,2/349,18/3769,0.1111111111111111,1.1999363260108244,0.2715873486384848,0.507016750952676,0.995170154694874,0.9910673490027657,CEP131/PLK4,2
R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,2/349,18/3769,0.1111111111111111,1.1999363260108244,0.2715873486384848,0.507016750952676,0.995170154694874,0.9910673490027657,CEP131/PLK4,2
R-HSA-5654687,Downstream signaling of activated FGFR1,2/349,18/3769,0.1111111111111111,1.1999363260108244,0.2715873486384848,0.507016750952676,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-199977,ER to Golgi Anterograde Transport,3/349,29/3769,0.10344827586206896,1.1171820966307677,0.2023389861340878,0.5115609816896116,0.995170154694874,0.9910673490027657,SPTBN5/TUBB6/SERPINA1,3
R-HSA-375280,Amine ligand-binding receptors,3/349,29/3769,0.10344827586206896,1.1171820966307677,0.2023389861340878,0.5115609816896116,0.995170154694874,0.9910673490027657,ADRA2A/DRD5/HTR1A,3
R-HSA-390466,Chaperonin-mediated protein folding,3/349,29/3769,0.10344827586206896,1.1171820966307677,0.2023389861340878,0.5115609816896116,0.995170154694874,0.9910673490027657,GNA14/FBXW5/TUBB6,3
R-HSA-1912422,Pre-NOTCH Expression and Processing,4/349,41/3769,0.0975609756097561,1.0536026277168218,0.11022882151949732,0.5345726529442251,0.995170154694874,0.9910673490027657,ATP2A3/NOTCH1/RUNX1/H3C2,4
R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,4/349,41/3769,0.0975609756097561,1.0536026277168218,0.11022882151949732,0.5345726529442251,0.995170154694874,0.9910673490027657,MTHFD2/NAMPT/VNN2/NUDT8,4
R-HSA-9855142,Cellular responses to mechanical stimuli,5/349,52/3769,0.09615384615384616,1.038406435970906,0.08907677933810723,0.5346540329205229,0.995170154694874,0.9910673490027657,RAMP2/ADM/CDH5/ITGB3/PECAM1,5
R-HSA-2995410,Nuclear Envelope (NE) Reassembly,2/349,19/3769,0.10526315789473684,1.1367817825365705,0.19091697004970334,0.5366830007688136,0.995170154694874,0.9910673490027657,LMNB1/TUBB6,2
R-HSA-69239,Synthesis of DNA,2/349,19/3769,0.10526315789473684,1.1367817825365705,0.19091697004970334,0.5366830007688136,0.995170154694874,0.9910673490027657,CDK2/CDT1,2
R-HSA-8955332,Carboxyterminal post-translational modifications of tubulin,2/349,19/3769,0.10526315789473684,1.1367817825365705,0.19091697004970334,0.5366830007688136,0.995170154694874,0.9910673490027657,TPGS1/TUBB6,2
R-HSA-1181150,Signaling by NODAL,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,CRIPTO,1
R-HSA-1236382,Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-156584,Cytosolic sulfonation of small molecules,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SLC26A1,1
R-HSA-168276,NS1 Mediated Effects on Host Pathways,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,ISG15,1
R-HSA-176408,Regulation of APC/C activators between G1/S and early anaphase,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-180336,SHC1 events in EGFR signaling,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-180786,Extension of Telomeres,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-1839130,Signaling by activated point mutants of FGFR3,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-190239,FGFR3 ligand binding and activation,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-190372,FGFR3c ligand binding and activation,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-202670,ERKs are inactivated,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,DUSP4,1
R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,TEAD4,1
R-HSA-2033514,FGFR3 mutant receptor activation,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-210744,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-2162123,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,PTGES,1
R-HSA-2453864,Retinoid cycle disease events,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,TTR,1
R-HSA-2474795,Diseases associated with visual transduction,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,TTR,1
R-HSA-389958,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-399956,CRMPs in Sema3A signaling,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,PLXNA1,1
R-HSA-400451,Free fatty acids regulate insulin secretion,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-418890,Role of second messengers in netrin-1 signaling,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,TRPC7,1
R-HSA-422085,"Synthesis, secretion, and deacylation of Ghrelin",1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,ACHE,1
R-HSA-425381,Bicarbonate transporters,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SLC4A5,1
R-HSA-445144,Signal transduction by L1,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-549132,Organic cation/anion/zwitterion transport,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-5576890,Phase 3 - rapid repolarisation,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,KCNE4,1
R-HSA-5637810,Constitutive Signaling by EGFRvIII,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-5637812,Signaling by EGFRvIII in Cancer,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-5637815,Signaling by Ligand-Responsive EGFR Variants in Cancer,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-5654227,Phospholipase C-mediated cascade; FGFR3,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-6804757,Regulation of TP53 Degradation,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-8849471,"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,CRK,1
R-HSA-8939243,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-8963889,Assembly of active LPL and LIPC lipase complexes,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,ANGPTL4,1
R-HSA-8982491,Glycogen metabolism,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,PYGL,1
R-HSA-9034015,Signaling by NTRK3 (TRKC),1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-933541,TRAF6 mediated IRF7 activation,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,IFNA5,1
R-HSA-9609523,Insertion of tail-anchored proteins into the endoplasmic reticulum membrane,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,BAG6,1
R-HSA-9668328,Sealing of the nuclear envelope (NE) by ESCRT-III,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9675143,Diseases of the neuronal system,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,TTR,1
R-HSA-9840309,Glycosphingolipid biosynthesis,1/349,8/3769,0.125,1.3499283667621778,0.3164663834985322,0.5407279176811479,0.995170154694874,0.9910673490027657,FUT1,1
R-HSA-9856651,MITF-M-dependent gene expression,4/349,42/3769,0.09523809523809523,1.0285168508664209,0.059361056349391324,0.5542080402447943,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/IRF4/BCL2A1,4
R-HSA-193648,NRAGE signals death through JNK,3/349,31/3769,0.0967741935483871,1.0451058323320086,0.0805469327692187,0.5578755058798265,0.995170154694874,0.9910673490027657,BAD/NGFR/ARHGEF16,3
R-HSA-204998,"Cell death signalling via NRAGE, NRIF and NADE",3/349,31/3769,0.0967741935483871,1.0451058323320086,0.0805469327692187,0.5578755058798265,0.995170154694874,0.9910673490027657,BAD/NGFR/ARHGEF16,3
R-HSA-391251,Protein folding,3/349,31/3769,0.0967741935483871,1.0451058323320086,0.0805469327692187,0.5578755058798265,0.995170154694874,0.9910673490027657,GNA14/FBXW5/TUBB6,3
R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,2/349,20/3769,0.1,1.0799426934097422,0.11449622327323762,0.5650997520926953,0.995170154694874,0.9910673490027657,CHST3/CHSY1,2
R-HSA-8854518,AURKA Activation by TPX2,2/349,20/3769,0.1,1.0799426934097422,0.11449622327323762,0.5650997520926953,0.995170154694874,0.9910673490027657,CEP131/PLK4,2
R-HSA-9833482,PKR-mediated signaling,2/349,20/3769,0.1,1.0799426934097422,0.11449622327323762,0.5650997520926953,0.995170154694874,0.9910673490027657,TUBB6/ISG15,2
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,6/349,65/3769,0.09230769230769231,0.9968701785320697,-0.008130099522796665,0.56666838490943094,0.995170154694874,0.9910673490027657,SIGLEC9/FCGR1A/B2M/SIGLEC7/CD300E/FCGR3A,6
R-HSA-5617833,Cilium Assembly,5/349,54/3769,0.09259259259259259,0.9999469383423538,-1.2544501032694052e-4,0.5693307633445397,0.995170154694874,0.9910673490027657,MCHR1/CEP131/PLK4/TUBB6/SSTR3,5
R-HSA-9705683,SARS-CoV-2-host interactions,5/349,54/3769,0.09259259259259259,0.9999469383423538,-1.2544501032694052e-4,0.5693307633445397,0.995170154694874,0.9910673490027657,NOD1/TLR2/IFNA5/B2M/ISG15,5
R-HSA-211945,Phase I - Functionalization of compounds,4/349,43/3769,0.09302325581395349,1.0045978543346437,0.009685523924356959,0.5733964226911288,0.995170154694874,0.9910673490027657,CYP3A43/POMC/CYP1B1/CYP26C1,4
R-HSA-3000178,ECM proteoglycans,4/349,43/3769,0.09302325581395349,1.0045978543346437,0.009685523924356959,0.5733964226911288,0.995170154694874,0.9910673490027657,COL5A3/COL9A3/COL4A1/ITGB3,4
R-HSA-9013406,RHOQ GTPase cycle,3/349,32/3769,0.09375,1.0124462750716332,0.02258436804852154,0.5800227843026353,0.995170154694874,0.9910673490027657,SLC1A5/TRIP10/SCRIB,3
R-HSA-9843745,Adipogenesis,3/349,32/3769,0.09375,1.0124462750716332,0.02258436804852154,0.5800227843026353,0.995170154694874,0.9910673490027657,MBD3/ANGPTL4/NR2F2,3
R-HSA-1630316,Glycosaminoglycan metabolism,6/349,66/3769,0.09090909090909091,0.9817660849179474,-0.04773425481750593,0.5820971216773089,0.995170154694874,0.9910673490027657,HS3ST1/HAS1/CHST3/CHSY1/SLC26A1/HYAL3,6
R-HSA-1250347,SHC1 events in ERBB4 signaling,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-1538133,G0 and Early G1,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-164938,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,B2M,1
R-HSA-174143,APC/C-mediated degradation of cell cycle proteins,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-190840,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-190872,Transport of connexons to the plasma membrane,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-196757,Metabolism of folate and pterines,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,MTHFD2,1
R-HSA-197264,Nicotinamide salvage,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,NAMPT,1
R-HSA-2033519,Activated point mutants of FGFR2,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-211981,Xenobiotics,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,CYP3A43,1
R-HSA-2214320,Anchoring fibril formation,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,COL4A1,1
R-HSA-2871837,FCERI mediated NF-kB activation,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,FCER1G,1
R-HSA-381038,XBP1(S) activates chaperone genes,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-381070,IRE1alpha activates chaperones,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-389977,Post-chaperonin tubulin folding pathway,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-391160,Signal regulatory protein family interactions,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,SFTPA2,1
R-HSA-416700,Other semaphorin interactions,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,PLXNA1,1
R-HSA-418038,Nucleotide-like (purinergic) receptors,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,P2RY6,1
R-HSA-450321,JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,NOD1,1
R-HSA-453276,Regulation of mitotic cell cycle,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-4641262,Disassembly of the destruction complex and recruitment of AXIN to the membrane,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,WNT8A,1
R-HSA-5627123,RHO GTPases activate PAKs,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,LIMK1,1
R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654221,Phospholipase C-mediated cascade; FGFR2,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654720,PI-3K cascade:FGFR4,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-74259,Purine catabolism,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,PNP,1
R-HSA-8941856,RUNX3 regulates NOTCH signaling,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-8956321,Nucleotide salvage,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,PNP,1
R-HSA-8963693,Aspartate and asparagine metabolism,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,GADL1,1
R-HSA-8963743,Digestion and absorption,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,SLC2A5,1
R-HSA-9033658,Blood group systems biosynthesis,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,FUT1,1
R-HSA-9615710,Late endosomal microautophagy,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,VPS28,1
R-HSA-9734009,Defective Intrinsic Pathway for Apoptosis,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-9824272,Somitogenesis,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-9830364,Formation of the nephric duct,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-9861718,Regulation of pyruvate metabolism,1/349,9/3769,0.1111111111111111,1.1999363260108244,0.19181128159722974,0.5833458269417913,0.995170154694874,0.9910673490027657,PDK1,1
R-HSA-6794362,Protein-protein interactions at synapses,4/349,44/3769,0.09090909090909091,0.9817660849179474,-0.03885959187711948,0.5921139790866967,0.995170154694874,0.9910673490027657,APBA2/LRFN1/LRRC4B/LRFN4,4
R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,2/349,21/3769,0.09523809523809523,1.0285168508664209,0.0418568486929957,0.5922434923192387,0.995170154694874,0.9910673490027657,CEP131/PLK4,2
R-HSA-5607764,CLEC7A (Dectin-1) signaling,2/349,21/3769,0.09523809523809523,1.0285168508664209,0.0418568486929957,0.5922434923192387,0.995170154694874,0.9910673490027657,IL1B/CARD9,2
R-HSA-69206,G1/S Transition,3/349,33/3769,0.09090909090909091,0.9817660849179474,-0.03360381395223732,0.6014592794967826,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/CDT1,3
R-HSA-69242,S Phase,3/349,33/3769,0.09090909090909091,0.9817660849179474,-0.03360381395223732,0.6014592794967826,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/CDT1,3
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,3/349,33/3769,0.09090909090909091,0.9817660849179474,-0.03360381395223732,0.6014592794967826,0.995170154694874,0.9910673490027657,THBS1/RUNX1/H3C2,3
R-HSA-9006936,Signaling by TGFB family members,5/349,56/3769,0.08928571428571429,0.9642345476872698,-0.08612919104304805,0.6026353868923354,0.995170154694874,0.9910673490027657,TIMP1/FGF2/F11R/INHBB/ITGB3,5
R-HSA-9013423,RAC3 GTPase cycle,4/349,45/3769,0.08888888888888889,0.9599490608086597,-0.08633148929772742,0.6103406936858052,0.995170154694874,0.9910673490027657,SLC1A5/ARAP3/RAC3/NOXA1,4
R-HSA-1483249,Inositol phosphate metabolism,2/349,22/3769,0.09090909090909091,0.9817660849179474,-0.027397095859132633,0.6181057264537099,0.995170154694874,0.9910673490027657,ITPKC/PLD4,2
R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,2/349,22/3769,0.09090909090909091,0.9817660849179474,-0.027397095859132633,0.6181057264537099,0.995170154694874,0.9910673490027657,FKBP5/TUBB6,2
R-HSA-446193,"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",2/349,22/3769,0.09090909090909091,0.9817660849179474,-0.027397095859132633,0.6181057264537099,0.995170154694874,0.9910673490027657,AMDHD2/MVD,2
R-HSA-446219,Synthesis of substrates in N-glycan biosythesis,2/349,22/3769,0.09090909090909091,0.9817660849179474,-0.027397095859132633,0.6181057264537099,0.995170154694874,0.9910673490027657,AMDHD2/MVD,2
R-HSA-8875878,MET promotes cell motility,2/349,22/3769,0.09090909090909091,0.9817660849179474,-0.027397095859132633,0.6181057264537099,0.995170154694874,0.9910673490027657,COL5A3/CRK,2
R-HSA-9759194,Nuclear events mediated by NFE2L2,2/349,22/3769,0.09090909090909091,0.9817660849179474,-0.027397095859132633,0.6181057264537099,0.995170154694874,0.9910673490027657,CCL2/NOTCH1,2
R-HSA-1187000,Fertilization,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,OVGP1,1
R-HSA-1234174,Cellular response to hypoxia,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,CITED2,1
R-HSA-186763,Downstream signal transduction,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,CRK,1
R-HSA-190241,FGFR2 ligand binding and activation,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-190242,FGFR1 ligand binding and activation,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-204005,COPII-mediated vesicle transport,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,SERPINA1,1
R-HSA-3772470,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,WNT9A,1
R-HSA-416993,Trafficking of GluR2-containing AMPA receptors,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,GRIP2,1
R-HSA-4791275,Signaling by WNT in cancer,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FZD8,1
R-HSA-5621480,Dectin-2 family,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FCER1G,1
R-HSA-5654710,PI-3K cascade:FGFR3,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654712,FRS-mediated FGFR4 signaling,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654733,Negative regulation of FGFR4 signaling,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-622312,Inflammasomes,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,NLRP1,1
R-HSA-6804758,Regulation of TP53 Activity through Acetylation,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,MBD3,1
R-HSA-69205,G1/S-Specific Transcription,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,CDT1,1
R-HSA-9006115,Signaling by NTRK2 (TRKB),1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9022699,MECP2 regulates neuronal receptors and channels,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,FKBP5,1
R-HSA-9665348,Signaling by ERBB2 ECD mutants,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9753281,Paracetamol ADME,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,ACY1,1
R-HSA-9843743,Transcriptional regulation of brown and beige adipocyte differentiation,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,MBD3,1
R-HSA-9844594,Transcriptional regulation of brown and beige adipocyte differentiation by EBF2,1/349,10/3769,0.1,1.0799426934097422,0.08085329456069924,0.6220193126857578,0.995170154694874,0.9910673490027657,MBD3,1
R-HSA-1989781,PPARA activates gene expression,3/349,34/3769,0.08823529411764706,0.9528906118321254,-0.08813668805633428,0.6221654057433224,0.995170154694874,0.9910673490027657,ABCB4/G0S2/ANGPTL4,3
R-HSA-373755,Semaphorin interactions,3/349,34/3769,0.08823529411764706,0.9528906118321254,-0.08813668805633428,0.6221654057433224,0.995170154694874,0.9910673490027657,LIMK1/PLXNA1/LIMK2,3
R-HSA-400206,Regulation of lipid metabolism by PPARalpha,3/349,34/3769,0.08823529411764706,0.9528906118321254,-0.08813668805633428,0.6221654057433224,0.995170154694874,0.9910673490027657,ABCB4/G0S2/ANGPTL4,3
R-HSA-2559583,Cellular Senescence,5/349,58/3769,0.08620689655172414,0.9309850805256399,-0.16918685316014487,0.6344366309435121,0.995170154694874,0.9910673490027657,LMNB1/CDK2/CDKN1A/IL6/H3C2,5
R-HSA-6806834,Signaling by MET,3/349,35/3769,0.08571428571428572,0.925665165779779,-0.14112187891918532,0.6421276221329122,0.995170154694874,0.9910673490027657,COL5A3/SHC1/CRK,3
R-HSA-162909,Host Interactions of HIV factors,2/349,23/3769,0.08695652173913043,0.9390806029649932,-0.09360320840329016,0.6426904115129755,0.995170154694874,0.9910673490027657,HCK/B2M,2
R-HSA-2428924,IGF1R signaling cascade,2/349,23/3769,0.08695652173913043,0.9390806029649932,-0.09360320840329016,0.6426904115129755,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-6807878,COPI-mediated anterograde transport,2/349,23/3769,0.08695652173913043,0.9390806029649932,-0.09360320840329016,0.6426904115129755,0.995170154694874,0.9910673490027657,SPTBN5/TUBB6,2
R-HSA-74751,Insulin receptor signalling cascade,2/349,23/3769,0.08695652173913043,0.9390806029649932,-0.09360320840329016,0.6426904115129755,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-2682334,EPH-Ephrin signaling,4/349,47/3769,0.0851063829787234,0.9191001646040358,-0.17826393546704228,0.6452592553744503,0.995170154694874,0.9910673490027657,LIMK1/EFNA1/LIMK2/EPHB3,4
R-HSA-1643713,Signaling by EGFR in Cancer,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-166663,Initial triggering of complement,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,C1R,1
R-HSA-167044,Signalling to RAS,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-176187,Activation of ATR in response to replication stress,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-209776,Metabolism of amine-derived hormones,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,DUOX1,1
R-HSA-390666,Serotonin receptors,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,HTR1A,1
R-HSA-3928664,Ephrin signaling,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,EPHB3,1
R-HSA-525793,Myogenesis,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,NTN3,1
R-HSA-5357786,TNFR1-induced proapoptotic signaling,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,MIB2,1
R-HSA-5576893,Phase 2 - plateau phase,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,KCNE4,1
R-HSA-5654689,PI-3K cascade:FGFR1,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654695,PI-3K cascade:FGFR2,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654706,FRS-mediated FGFR3 signaling,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654732,Negative regulation of FGFR3 signaling,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5658442,Regulation of RAS by GAPs,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,RASAL3,1
R-HSA-5682910,LGI-ADAM interactions,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,ADAM11,1
R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-8950505,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-9006335,Signaling by Erythropoietin,1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9615017,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,POMC,1
R-HSA-9860927,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1/349,11/3769,0.09090909090909091,0.9817660849179474,-0.019344298721866996,0.6571124916888627,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-1912408,Pre-NOTCH Transcription and Translation,3/349,36/3769,0.08333333333333333,0.8999522445081184,-0.19265696433349871,0.6613378250145208,0.995170154694874,0.9910673490027657,NOTCH1/RUNX1/H3C2,3
R-HSA-74752,Signaling by Insulin receptor,3/349,36/3769,0.08333333333333333,0.8999522445081184,-0.19265696433349871,0.6613378250145208,0.995170154694874,0.9910673490027657,CTSD/FGF2/SHC1,3
R-HSA-948021,Transport to the Golgi and subsequent modification,3/349,36/3769,0.08333333333333333,0.8999522445081184,-0.19265696433349871,0.6613378250145208,0.995170154694874,0.9910673490027657,SPTBN5/TUBB6/SERPINA1,3
R-HSA-8978868,Fatty acid metabolism,5/349,60/3769,0.08333333333333333,0.8999522445081184,-0.24952247298041422,0.6646385214478976,0.995170154694874,0.9910673490027657,CYP1B1/PTGES/THRSP/DPEP2/ACSL5,5
R-HSA-195258,RHO GTPase Effectors,10/349,118/3769,0.0847457627118644,0.9152056723811373,-0.29892139163650233,0.6651800601932383,0.995170154694874,0.9910673490027657,LIMK1/RAC2/S100A8/RHPN1/S100A9/PPP1R14A/TUBB6/LIMK2/NOXA1/H3C2,10
R-HSA-1222556,ROS and RNS production in phagocytes,2/349,24/3769,0.08333333333333333,0.8999522445081184,-0.1570515284256573,0.6660117351536857,0.995170154694874,0.9910673490027657,SLC11A1/RAC2,2
R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),2/349,24/3769,0.08333333333333333,0.8999522445081184,-0.1570515284256573,0.6660117351536857,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,2/349,24/3769,0.08333333333333333,0.8999522445081184,-0.1570515284256573,0.6660117351536857,0.995170154694874,0.9910673490027657,ANGPTL4/NR2F2,2
R-HSA-5620912,Anchoring of the basal body to the plasma membrane,2/349,24/3769,0.08333333333333333,0.8999522445081184,-0.1570515284256573,0.6660117351536857,0.995170154694874,0.9910673490027657,CEP131/PLK4,2
R-HSA-5654736,Signaling by FGFR1,2/349,24/3769,0.08333333333333333,0.8999522445081184,-0.1570515284256573,0.6660117351536857,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-15869,Metabolism of nucleotides,3/349,37/3769,0.08108108108108109,0.875629210872764,-0.24283067212152268,0.6797927694509487,0.995170154694874,0.9910673490027657,NME3/GLRX/PNP,3
R-HSA-1280218,Adaptive Immune System,23/349,268/3769,0.08582089552238806,0.9268164906128383,-0.3970449536652556,0.6868828089333042,0.995170154694874,0.9910673490027657,KIF26A/CD209/BLNK/CTSD/SIGLEC9/PTPN22/TLR2/S100A8/FCGR1A/LY96/FBXW5/S100A9/FBXO40/B2M/SIGLEC7/CD14/SPSB1/SPSB4/TUBB6/SOCS3/CD300E/MIB2/FCGR3A,23
R-HSA-5654738,Signaling by FGFR2,2/349,25/3769,0.08,0.8639541547277937,-0.21799296335445223,0.6880921970512559,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-1482788,Acyl chain remodelling of PC,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,LPCAT1,1
R-HSA-1839126,FGFR2 mutant receptor activation,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-192105,Synthesis of bile acids and bile salts,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,CH25H,1
R-HSA-196071,Metabolism of steroid hormones,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,POMC,1
R-HSA-350054,Notch-HLH transcription pathway,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-388844,Receptor-type tyrosine-protein phosphatases,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,LRRC4B,1
R-HSA-420029,Tight junction interactions,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,F11R,1
R-HSA-5654693,FRS-mediated FGFR1 signaling,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654700,FRS-mediated FGFR2 signaling,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5654727,Negative regulation of FGFR2 signaling,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5655332,Signaling by FGFR3 in disease,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-72306,tRNA processing,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,ADAT3,1
R-HSA-888590,"GABA synthesis, release, reuptake and degradation",1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,CPLX1,1
R-HSA-9013695,NOTCH4 Intracellular Domain Regulates Transcription,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-9768919,NPAS4 regulates expression of target genes,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,NAMPT,1
R-HSA-9856532,Mechanical load activates signaling by PIEZO1 and integrins in osteocytes,1/349,12/3769,0.08333333333333333,0.8999522445081184,-0.11087470643799649,0.6889559564042929,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,6/349,74/3769,0.08108108108108109,0.875629210872764,-0.3451295426423923,0.6944472112257436,0.995170154694874,0.9910673490027657,FBXW5/FBXO40/SPSB1/SPSB4/SOCS3/MIB2,6
R-HSA-1500620,Meiosis,3/349,38/3769,0.07894736842105263,0.8525863369024279,-0.2917239057282303,0.6974935223898903,0.995170154694874,0.9910673490027657,LMNB1/CDK2/H3C2,3
R-HSA-453279,Mitotic G1 phase and G1/S transition,3/349,38/3769,0.07894736842105263,0.8525863369024279,-0.2917239057282303,0.6974935223898903,0.995170154694874,0.9910673490027657,CDK2/CDKN1A/CDT1,3
R-HSA-446203,Asparagine N-linked glycosylation,5/349,63/3769,0.07936507936507936,0.8570973757220175,-0.36535316930101325,0.7068107471656426,0.995170154694874,0.9910673490027657,SPTBN5/AMDHD2/MVD/TUBB6/SERPINA1,5
R-HSA-157118,Signaling by NOTCH,6/349,75/3769,0.08,0.8639541547277937,-0.3801216248217145,0.7069802623995713,0.995170154694874,0.9910673490027657,ATP2A3/NOTCH1/RUNX1/JAG2/MIB2/H3C2,6
R-HSA-68877,Mitotic Prometaphase,4/349,51/3769,0.0784313725490196,0.8470138771841115,-0.35134804482470233,0.7086963107101363,0.995170154694874,0.9910673490027657,CEP131/PLK4/MZT2B/TUBB6,4
R-HSA-168928,DDX58/IFIH1-mediated induction of interferon-alpha/beta,2/349,26/3769,0.07692307692307693,0.8307251487767249,-0.2766459449220353,0.7089609562509882,0.995170154694874,0.9910673490027657,IFNA5/ISG15,2
R-HSA-8876198,RAB GEFs exchange GTP for GDP on RABs,2/349,26/3769,0.07692307692307693,0.8307251487767249,-0.2766459449220353,0.7089609562509882,0.995170154694874,0.9910673490027657,DENND2D/TRAPPC12,2
R-HSA-9679506,SARS-CoV Infections,10/349,123/3769,0.08130081300813008,0.878002189764018,-0.43939121196669084,0.7159235844802532,0.995170154694874,0.9910673490027657,MBD3/BLNK/JAK3/NOD1/IL1R1/TLR2/IFNA5/RUNX1/B2M/ISG15,10
R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian expression",1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,NAMPT,1
R-HSA-181430,Norepinephrine Neurotransmitter Release Cycle,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,CPLX1,1
R-HSA-1839124,FGFR1 mutant receptor activation,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-198753,ERK/MAPK targets,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,DUSP4,1
R-HSA-3295583,TRP channels,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,TRPC7,1
R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,SOX17,1
R-HSA-428930,Thromboxane signalling through TP receptor,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-5218920,VEGFR2 mediated vascular permeability,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,CDH5,1
R-HSA-5576886,Phase 4 - resting membrane potential,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,KCNK9,1
R-HSA-5626467,RHO GTPases activate IQGAPs,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-5654726,Negative regulation of FGFR1 signaling,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5674135,MAP2K and MAPK activation,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-75876,Synthesis of very long-chain fatty acyl-CoAs,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,ACSL5,1
R-HSA-77387,Insulin receptor recycling,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,CTSD,1
R-HSA-936440,Negative regulators of DDX58/IFIH1 signaling,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,ISG15,1
R-HSA-9749641,Aspirin ADME,1/349,13/3769,0.07692307692307693,0.8307251487767249,-0.1952794002704294,0.7178498534537743,0.995170154694874,0.9910673490027657,GLYATL1,1
R-HSA-201681,TCF dependent signaling in response to WNT,6/349,76/3769,0.07894736842105263,0.8525863369024279,-0.41467703822327495,0.7191616727416792,0.995170154694874,0.9910673490027657,WNT8A/LGR6/WNT9A/SOX17/FZD8/H3C2,6
R-HSA-9734767,Developmental Cell Lineages,5/349,64/3769,0.078125,0.843705229226361,-0.4028055411226485,0.7200173321050123,0.995170154694874,0.9910673490027657,COL5A3/FGF2/CPB1/SOX17/BHLHA15,5
R-HSA-71387,Metabolism of carbohydrates and carbohydrate derivatives,9/349,112/3769,0.08035714285714286,0.8678110929185429,-0.45362465467013313,0.7230838256003989,0.995170154694874,0.9910673490027657,HS3ST1/PYGL/HAS1/CHST3/CHSY1/SLC26A1/HK2/FUT1/HYAL3,9
R-HSA-1483206,Glycerophospholipid biosynthesis,4/349,52/3769,0.07692307692307693,0.8307251487767249,-0.3926023904256314,0.7231998338592707,0.995170154694874,0.9910673490027657,ACHE/LPCAT1/PLD4/CPNE7,4
R-HSA-2219528,PI3K/AKT Signaling in Cancer,4/349,52/3769,0.07692307692307693,0.8307251487767249,-0.3926023904256314,0.7231998338592707,0.995170154694874,0.9910673490027657,BAD/CDKN1A/RAC2/FGF2,4
R-HSA-1566948,Elastic fibre formation,2/349,27/3769,0.07407407407407407,0.799957550673883,-0.3332017405983523,0.7286524118993939,0.995170154694874,0.9910673490027657,LOXL4/ITGB3,2
R-HSA-427389,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,2/349,27/3769,0.07407407407407407,0.799957550673883,-0.3332017405983523,0.7286524118993939,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-450294,MAP kinase activation,2/349,27/3769,0.07407407407407407,0.799957550673883,-0.3332017405983523,0.7286524118993939,0.995170154694874,0.9910673490027657,NOD1/DUSP4,2
R-HSA-6809371,Formation of the cornified envelope,2/349,27/3769,0.07407407407407407,0.799957550673883,-0.3332017405983523,0.7286524118993939,0.995170154694874,0.9910673490027657,DSC2/PKP3,2
R-HSA-917937,Iron uptake and transport,2/349,27/3769,0.07407407407407407,0.799957550673883,-0.3332017405983523,0.7286524118993939,0.995170154694874,0.9910673490027657,CP/STEAP4,2
R-HSA-9748784,Drug ADME,3/349,40/3769,0.075,0.8099570200573066,-0.38595861847405344,0.7306552348240958,0.995170154694874,0.9910673490027657,GLYATL1/PNP/ACY1,3
R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,21/349,253/3769,0.08300395256916997,0.896395121012039,-0.5449681769696767,0.7395676127581776,0.995170154694874,0.9910673490027657,PRDM1/COL5A3/COL9A3/LYL1/JAK3/ADAP1/F3/CTSD/DUSP4/VGF/EGR4/THBS1/FGF2/ADCYAP1/SHC1/SH2B2/CRK/CDH5/COL4A1/ARC/ITGB3,21
R-HSA-111465,Apoptotic cleavage of cellular proteins,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-114452,Activation of BH3-only proteins,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,BAD,1
R-HSA-1250196,SHC1 events in ERBB2 signaling,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-1660661,Sphingolipid de novo biosynthesis,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,SPHK2,1
R-HSA-191273,Cholesterol biosynthesis,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,MVD,1
R-HSA-196807,Nicotinate metabolism,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,NAMPT,1
R-HSA-449836,Other interleukin signaling,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,CSF3,1
R-HSA-75105,Fatty acyl-CoA biosynthesis,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,ACSL5,1
R-HSA-9020591,Interleukin-12 signaling,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-9607240,FLT3 Signaling,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,HCK,1
R-HSA-9619483,Activation of AMPK downstream of NMDARs,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9660826,Purinergic signaling in leishmaniasis infection,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,IL1B,1
R-HSA-9664424,Cell recruitment (pro-inflammatory response),1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,IL1B,1
R-HSA-9717207,"Sensory perception of sweet, bitter, and umami (glutamate) taste",1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,CALHM1,1
R-HSA-9824585,Regulation of MITF-M-dependent genes involved in pigmentation,1/349,14/3769,0.07142857142857142,0.7713876381498158,-0.27372462228814315,0.7440666801695978,0.995170154694874,0.9910673490027657,IRF4,1
R-HSA-392499,Metabolism of proteins,49/349,572/3769,0.08566433566433566,0.9251257338649889,-0.6210325774794152,0.755451857634918,0.995170154694874,0.9910673490027657,TMEM132A/PLAUR/CP/ACHE/LYZ/CSF2RB/TIMP1/EEF1D/NOD1/CALCA/VNN2/CISH/POMC/CTSD/TTR/CDKN1A/VGF/IL6/THBS1/SPTBN5/RAB20/TPGS1/LYPD6B/ADRA2A/PDK1/CPB1/GNA14/FBXW5/JOSD2/AMDHD2/INHBB/ADAMTS9/FBXO40/MELTF/B2M/MVD/RAB24/SPSB1/RAB43/SPSB4/TUBB6/LY6H/SOCS3/SFTPA2/NTNG2/SERPINA1/ADAMTSL2/MRPL12/H3C2,49
R-HSA-8878171,Transcriptional regulation by RUNX1,5/349,67/3769,0.07462686567164178,0.8059273831415985,-0.5119629861642442,0.7570765998049434,0.995170154694874,0.9910673490027657,THBS1/RUNX1/SOCS3/CR1/H3C2,5
R-HSA-5633007,Regulation of TP53 Activity,3/349,42/3769,0.07142857142857142,0.7713876381498158,-0.4758825354708373,0.7608990846884036,0.995170154694874,0.9910673490027657,PRDM1/MBD3/CDK2,3
R-HSA-69002,DNA Replication Pre-Initiation,3/349,42/3769,0.07142857142857142,0.7713876381498158,-0.4758825354708373,0.7608990846884036,0.995170154694874,0.9910673490027657,CDK2/CDT1/H3C2,3
R-HSA-448424,Interleukin-17 signaling,2/349,29/3769,0.06896551724137931,0.7447880644205117,-0.4406758863274439,0.7646601001087943,0.995170154694874,0.9910673490027657,NOD1/DUSP4,2
R-HSA-114508,Effects of PIP2 hydrolysis,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,TRPC7,1
R-HSA-1433557,Signaling by SCF-KIT,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,SH2B2,1
R-HSA-1483166,Synthesis of PA,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,LPCAT1,1
R-HSA-181429,Serotonin Neurotransmitter Release Cycle,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,CPLX1,1
R-HSA-2980766,Nuclear Envelope Breakdown,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-3371453,Regulation of HSF1-mediated heat shock response,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,HSPA12B,1
R-HSA-3928663,EPHA-mediated growth cone collapse,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,EFNA1,1
R-HSA-418592,ADP signalling through P2Y purinoceptor 1,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-447115,Interleukin-12 family signaling,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-5655302,Signaling by FGFR1 in disease,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-6814122,Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-69273,Cyclin A/B1/B2 associated events during G2/M transition,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-8943724,Regulation of PTEN gene transcription,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,MBD3,1
R-HSA-8964038,LDL clearance,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,LSR,1
R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-9665686,Signaling by ERBB2 TMD/JMD mutants,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9692916,SARS-CoV-1 activates/modulates innate immune responses,1/349,15/3769,0.06666666666666667,0.7199617956064948,-0.3471130064816693,0.7678538249421172,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-1852241,Organelle biogenesis and maintenance,6/349,81/3769,0.07407407407407407,0.799957550673883,-0.5813321263561751,0.7747727677873666,0.995170154694874,0.9910673490027657,ATP5F1D/MCHR1/CEP131/PLK4/TUBB6/SSTR3,6
R-HSA-1428517,Aerobic respiration and respiratory electron transport,3/349,43/3769,0.06976744186046512,0.7534483907509829,-0.5193686742046439,0.7749617843381992,0.995170154694874,0.9910673490027657,ATP5F1D/PDK1/GPT,3
R-HSA-162906,HIV Infection,3/349,43/3769,0.06976744186046512,0.7534483907509829,-0.5193686742046439,0.7749617843381992,0.995170154694874,0.9910673490027657,HCK/VPS28/B2M,3
R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,3/349,43/3769,0.06976744186046512,0.7534483907509829,-0.5193686742046439,0.7749617843381992,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA,3
R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,3/349,43/3769,0.06976744186046512,0.7534483907509829,-0.5193686742046439,0.7749617843381992,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA,3
R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,3/349,43/3769,0.06976744186046512,0.7534483907509829,-0.5193686742046439,0.7749617843381992,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA,3
R-HSA-975871,MyD88 cascade initiated on plasma membrane,3/349,43/3769,0.06976744186046512,0.7534483907509829,-0.5193686742046439,0.7749617843381992,0.995170154694874,0.9910673490027657,NOD1/DUSP4/TIFA,3
R-HSA-3858494,Beta-catenin independent WNT signaling,4/349,56/3769,0.07142857142857142,0.7713876381498158,-0.5505368034053492,0.7758585054566186,0.995170154694874,0.9910673490027657,RAC2/RAC3/FZD8/SCRIB,4
R-HSA-195721,Signaling by WNT,10/349,130/3769,0.07692307692307693,0.8307251487767249,-0.6273764271752741,0.7782198843144537,0.995170154694874,0.9910673490027657,WNT8A/RAC2/LGR6/WNT9A/WNT7A/SOX17/RAC3/FZD8/SCRIB/H3C2,10
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,13/349,166/3769,0.0783132530120482,0.8457382538750993,-0.6492848409798311,0.7803437802918844,0.995170154694874,0.9910673490027657,BAD/CDKN1A/RAC2/PIM1/IRF4/FGF2/BCL2A1/NOTCH1/SHC1/FZD8/JAG2/MIB2/ITGB3,13
R-HSA-112310,Neurotransmitter release cycle,2/349,30/3769,0.06666666666666667,0.7199617956064948,-0.49187560806410346,0.7810612710178142,0.995170154694874,0.9910673490027657,CPLX1/SLC18A3,2
R-HSA-1236394,Signaling by ERBB4,2/349,30/3769,0.06666666666666667,0.7199617956064948,-0.49187560806410346,0.7810612710178142,0.995170154694874,0.9910673490027657,ADAP1/SHC1,2
R-HSA-418597,G alpha (z) signalling events,2/349,30/3769,0.06666666666666667,0.7199617956064948,-0.49187560806410346,0.7810612710178142,0.995170154694874,0.9910673490027657,RGS16/ADRA2A,2
R-HSA-5250913,Positive epigenetic regulation of rRNA expression,2/349,30/3769,0.06666666666666667,0.7199617956064948,-0.49187560806410346,0.7810612710178142,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-6805567,Keratinization,2/349,30/3769,0.06666666666666667,0.7199617956064948,-0.49187560806410346,0.7810612710178142,0.995170154694874,0.9910673490027657,DSC2/PKP3,2
R-HSA-9013409,RHOJ GTPase cycle,2/349,30/3769,0.06666666666666667,0.7199617956064948,-0.49187560806410346,0.7810612710178142,0.995170154694874,0.9910673490027657,SLC1A5/SCRIB,2
R-HSA-983189,Kinesins,2/349,30/3769,0.06666666666666667,0.7199617956064948,-0.49187560806410346,0.7810612710178142,0.995170154694874,0.9910673490027657,KIF26A/TUBB6,2
R-HSA-4420097,VEGFA-VEGFR2 Pathway,3/349,44/3769,0.06818181818181818,0.7363245636884604,-0.5619374553944896,0.7883408920395285,0.995170154694874,0.9910673490027657,CRK/CDH5/ITGB3,3
R-HSA-9818564,Epigenetic regulation of gene expression by MLL3 and MLL4 complexes,3/349,44/3769,0.06818181818181818,0.7363245636884604,-0.5619374553944896,0.7883408920395285,0.995170154694874,0.9910673490027657,THRSP/ANGPTL4/H3C2,3
R-HSA-9841922,MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,3/349,44/3769,0.06818181818181818,0.7363245636884604,-0.5619374553944896,0.7883408920395285,0.995170154694874,0.9910673490027657,THRSP/ANGPTL4/H3C2,3
R-HSA-9851695,Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes,3/349,44/3769,0.06818181818181818,0.7363245636884604,-0.5619374553944896,0.7883408920395285,0.995170154694874,0.9910673490027657,THRSP/ANGPTL4/H3C2,3
R-HSA-1251985,Nuclear signaling by ERBB4,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,ADAP1,1
R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,IFI16,1
R-HSA-212676,Dopamine Neurotransmitter Release Cycle,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,CPLX1,1
R-HSA-2426168,Activation of gene expression by SREBF (SREBP),1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,MVD,1
R-HSA-392518,Signal amplification,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-5357905,Regulation of TNFR1 signaling,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,MIB2,1
R-HSA-5620924,Intraflagellar transport,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-5655253,Signaling by FGFR2 in disease,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-5669034,TNFs bind their physiological receptors,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,TNFRSF1B,1
R-HSA-5689896,Ovarian tumor domain proteases,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,NOD1,1
R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-6802949,Signaling by RAS mutants,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-8956319,Nucleotide catabolism,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,PNP,1
R-HSA-9634815,Transcriptional Regulation by NPAS4,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,NAMPT,1
R-HSA-9646399,Aggrephagy,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9649948,Signaling downstream of RAS mutants,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-9656223,Signaling by RAF1 mutants,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-9717189,Sensory perception of taste,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,CALHM1,1
R-HSA-9793380,Formation of paraxial mesoderm,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1/349,16/3769,0.0625,0.6749641833810889,-0.4161568392817691,0.7894358747810093,0.995170154694874,0.9910673490027657,BLNK,1
R-HSA-3928665,EPH-ephrin mediated repulsion of cells,2/349,31/3769,0.06451612903225806,0.6967372215546723,-0.5415460787209145,0.7964533927514685,0.995170154694874,0.9910673490027657,EFNA1/EPHB3,2
R-HSA-73854,RNA Polymerase I Promoter Clearance,2/349,31/3769,0.06451612903225806,0.6967372215546723,-0.5415460787209145,0.7964533927514685,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-73864,RNA Polymerase I Transcription,2/349,31/3769,0.06451612903225806,0.6967372215546723,-0.5415460787209145,0.7964533927514685,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-912446,Meiotic recombination,2/349,31/3769,0.06451612903225806,0.6967372215546723,-0.5415460787209145,0.7964533927514685,0.995170154694874,0.9910673490027657,CDK2/H3C2,2
R-HSA-9843940,Regulation of endogenous retroelements by KRAB-ZFP proteins,2/349,31/3769,0.06451612903225806,0.6967372215546723,-0.5415460787209145,0.7964533927514685,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-1227990,Signaling by ERBB2 in Cancer,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-1660662,Glycosphingolipid metabolism,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,FUT1,1
R-HSA-190861,Gap junction assembly,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-210500,Glutamate Neurotransmitter Release Cycle,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,CPLX1,1
R-HSA-3214841,PKMTs methylate histone lysines,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-3214842,HDMs demethylate histones,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-400042,"Adrenaline,noradrenaline inhibits insulin secretion",1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,ADRA2A,1
R-HSA-425397,"Transport of vitamins, nucleosides, and related molecules",1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,SLC29A4,1
R-HSA-445355,Smooth Muscle Contraction,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,CACNA1G,1
R-HSA-5619084,ABC transporter disorders,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,ABCB4,1
R-HSA-9013407,RHOH GTPase cycle,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,SLC1A5,1
R-HSA-9664565,Signaling by ERBB2 KD Mutants,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9707616,Heme signaling,1/349,17/3769,0.058823529411764705,0.6352604078880836,-0.48142768525651575,0.8090167113654558,0.995170154694874,0.9910673490027657,LY96,1
R-HSA-170834,Signaling by TGF-beta Receptor Complex,2/349,32/3769,0.0625,0.6749641833810889,-0.5897932087491577,0.8108820999813906,0.995170154694874,0.9910673490027657,F11R/ITGB3,2
R-HSA-190236,Signaling by FGFR,2/349,33/3769,0.06060606060606061,0.6545107232786316,-0.6367122653140599,0.8243932496900752,0.995170154694874,0.9910673490027657,FGF2/SHC1,2
R-HSA-9662361,Sensory processing of sound by outer hair cells of the cochlea,2/349,33/3769,0.06060606060606061,0.6545107232786316,-0.6367122653140599,0.8243932496900752,0.995170154694874,0.9910673490027657,CDH23/CHRNA10,2
R-HSA-9845323,Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs),2/349,33/3769,0.06060606060606061,0.6545107232786316,-0.6367122653140599,0.8243932496900752,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-109704,PI3K Cascade,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-1655829,Regulation of cholesterol biosynthesis by SREBP (SREBF),1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,MVD,1
R-HSA-194068,Bile acid and bile salt metabolism,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,CH25H,1
R-HSA-399719,Trafficking of AMPA receptors,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,GRIP2,1
R-HSA-399721,"Glutamate binding, activation of AMPA receptors and synaptic plasticity",1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,GRIP2,1
R-HSA-5687128,MAPK6/MAPK4 signaling,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,RAG1,1
R-HSA-75153,Apoptotic execution phase,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-75893,TNF signaling,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,MIB2,1
R-HSA-8963899,Plasma lipoprotein remodeling,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,ANGPTL4,1
R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,1/349,18/3769,0.05555555555555555,0.5999681630054122,-0.5433909292424459,0.8267814149191487,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-73857,RNA Polymerase II Transcription,28/349,351/3769,0.07977207977207977,0.8614927468795663,-0.870352443575675,0.8330520309403673,0.995170154694874,0.9910673490027657,PRDM1/MBD3/FKBP5/NAMPT/BCL6/POMC/GADD45A/ELL2/TNFRSF10B/ZNF205/CDK2/CDKN1A/IL6/THBS1/NOTCH1/RUNX1/CITED2/TNFRSF10D/TNFRSF10C/NABP1/NR2F1/SOCS3/ZNF775/TEAD4/ZNF442/CR1/ZIM2/H3C2,28
R-HSA-69306,DNA Replication,3/349,48/3769,0.0625,0.6749641833810889,-0.7238975569440059,0.8354127702546175,0.995170154694874,0.9910673490027657,CDK2/CDT1/H3C2,3
R-HSA-9917777,Epigenetic regulation by WDR5-containing histone modifying complexes,3/349,48/3769,0.0625,0.6749641833810889,-0.7238975569440059,0.8354127702546175,0.995170154694874,0.9910673490027657,THRSP/ANGPTL4/H3C2,3
R-HSA-3214815,HDACs deacetylate histones,2/349,34/3769,0.058823529411764705,0.6352604078880836,-0.6823892413377729,0.8370324899367472,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-6811434,COPI-dependent Golgi-to-ER retrograde traffic,2/349,34/3769,0.058823529411764705,0.6352604078880836,-0.6823892413377729,0.8370324899367472,0.995170154694874,0.9910673490027657,KIF26A/TUBB6,2
R-HSA-9824439,Bacterial Infection Pathways,2/349,34/3769,0.058823529411764705,0.6352604078880836,-0.6823892413377729,0.8370324899367472,0.995170154694874,0.9910673490027657,TLR2/B2M,2
R-HSA-1296041,Activation of G protein gated Potassium channels,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,KCNJ16,1
R-HSA-1296059,G protein gated Potassium channels,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,KCNJ16,1
R-HSA-186712,Regulation of beta-cell development,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-202403,TCR signaling,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,PTPN22,1
R-HSA-2173789,TGF-beta receptor signaling activates SMADs,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-3000157,Laminin interactions,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,COL4A1,1
R-HSA-445095,Interaction between L1 and Ankyrins,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,SPTBN5,1
R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,DUSP4,1
R-HSA-451326,Activation of kainate receptors upon glutamate binding,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,NCALD,1
R-HSA-456926,Thrombin signalling through proteinase activated receptors (PARs),1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-8874081,MET activates PTK2 signaling,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,COL5A3,1
R-HSA-9013694,Signaling by NOTCH4,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-917977,Transferrin endocytosis and recycling,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,STEAP4,1
R-HSA-9696264,RND3 GTPase cycle,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,SCRIB,1
R-HSA-997272,Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits,1/349,19/3769,0.05263157894736842,0.5683908912682852,-0.6024303950190196,0.8428979934830563,0.995170154694874,0.9910673490027657,KCNJ16,1
R-HSA-2132295,MHC class II antigen presentation,3/349,49/3769,0.061224489795918366,0.6611894041284135,-0.7624979167457487,0.8456749256683107,0.995170154694874,0.9910673490027657,KIF26A/CTSD/TUBB6,3
R-HSA-418346,Platelet homeostasis,3/349,49/3769,0.061224489795918366,0.6611894041284135,-0.7624979167457487,0.8456749256683107,0.995170154694874,0.9910673490027657,TRPC7/ATP2A3/PECAM1,3
R-HSA-196854,Metabolism of vitamins and cofactors,5/349,76/3769,0.06578947368421052,0.7104886140853566,-0.8144002497484728,0.8461428008574928,0.995170154694874,0.9910673490027657,MTHFD2/NAMPT/VNN2/TTR/NUDT8,5
R-HSA-8878166,Transcriptional regulation by RUNX2,2/349,35/3769,0.05714285714285714,0.6171101105198527,-0.7269020128910022,0.8488449061672827,0.995170154694874,0.9910673490027657,CDKN1A/RUNX1,2
R-HSA-9610379,HCMV Late Events,2/349,35/3769,0.05714285714285714,0.6171101105198527,-0.7269020128910022,0.8488449061672827,0.995170154694874,0.9910673490027657,VPS28/H3C2,2
R-HSA-977443,GABA receptor activation,2/349,35/3769,0.05714285714285714,0.6171101105198527,-0.7269020128910022,0.8488449061672827,0.995170154694874,0.9910673490027657,GABRA6/KCNJ16,2
R-HSA-194138,Signaling by VEGF,3/349,50/3769,0.06,0.6479656160458452,-0.8004092602641321,0.8553786611174312,0.995170154694874,0.9910673490027657,CRK/CDH5/ITGB3,3
R-HSA-9609646,HCMV Infection,3/349,50/3769,0.06,0.6479656160458452,-0.8004092602641321,0.8553786611174312,0.995170154694874,0.9910673490027657,VPS28/TUBB6/H3C2,3
R-HSA-373760,L1CAM interactions,4/349,64/3769,0.0625,0.6749641833810889,-0.837687834016164,0.8572535276025068,0.995170154694874,0.9910673490027657,CNTN6/SPTBN5/TUBB6/ITGB3,4
R-HSA-112399,IRS-mediated signalling,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-1169408,ISG15 antiviral mechanism,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,ISG15,1
R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,NOTCH1,1
R-HSA-6811436,COPI-independent Golgi-to-ER retrograde traffic,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-8853659,RET signaling,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9035034,RHOF GTPase cycle,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-9696270,RND2 GTPase cycle,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,SCRIB,1
R-HSA-9696273,RND1 GTPase cycle,1/349,20/3769,0.05,0.5399713467048711,-0.6588662597318383,0.8575189535562331,0.995170154694874,0.9910673490027657,PLXNA1,1
R-HSA-5663205,Infectious disease,25/349,322/3769,0.07763975155279502,0.8384648240758866,-0.9681207100437296,0.858380976897002,0.995170154694874,0.9910673490027657,MBD3/CD209/BLNK/HCK/JAK3/NOD1/IL1R1/IL1B/IL6/TLR2/FCGR2A/IFNA5/FCGR1A/LY96/RUNX1/VPS28/B2M/CRK/DPEP2/CD14/TUBB6/ISG15/NOXA1/FCGR3A/H3C2,25
R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,2/349,36/3769,0.05555555555555555,0.5999681630054122,-0.7703213227845385,0.8598747344703862,0.995170154694874,0.9910673490027657,FCER1G/SHC1,2
R-HSA-5625740,RHO GTPases activate PKNs,2/349,36/3769,0.05555555555555555,0.5999681630054122,-0.7703213227845385,0.8598747344703862,0.995170154694874,0.9910673490027657,PPP1R14A/H3C2,2
R-HSA-68867,Assembly of the pre-replicative complex,2/349,36/3769,0.05555555555555555,0.5999681630054122,-0.7703213227845385,0.8598747344703862,0.995170154694874,0.9910673490027657,CDT1/H3C2,2
R-HSA-1257604,PIP3 activates AKT signaling,6/349,91/3769,0.06593406593406594,0.7120501275229069,-0.8881510462761655,0.8606178024076863,0.995170154694874,0.9910673490027657,BAD/MBD3/IL1RL1/CDKN1A/RAC2/FGF2,6
R-HSA-5173105,O-linked glycosylation,3/349,51/3769,0.058823529411764705,0.6352604078880836,-0.837661221814898,0.8645463080178873,0.995170154694874,0.9910673490027657,THBS1/ADAMTS9/ADAMTSL2,3
R-HSA-9711123,Cellular response to chemical stress,3/349,51/3769,0.058823529411764705,0.6352604078880836,-0.837661221814898,0.8645463080178873,0.995170154694874,0.9910673490027657,CCL2/CDKN1A/NOTCH1,3
R-HSA-9824446,Viral Infection Pathways,17/349,229/3769,0.07423580786026202,0.8017041828805948,-0.9889737647645783,0.8675817837209485,0.995170154694874,0.9910673490027657,MBD3/CD209/BLNK/HCK/JAK3/NOD1/IL1R1/TLR2/IFNA5/LY96/RUNX1/VPS28/B2M/CD14/TUBB6/ISG15/H3C2,17
R-HSA-428157,Sphingolipid metabolism,2/349,37/3769,0.05405405405405406,0.5837528072485093,-0.8127116205810615,0.8701651324714971,0.995170154694874,0.9910673490027657,SPHK2/FUT1,2
R-HSA-9007101,Rab regulation of trafficking,2/349,37/3769,0.05405405405405406,0.5837528072485093,-0.8127116205810615,0.8701651324714971,0.995170154694874,0.9910673490027657,DENND2D/TRAPPC12,2
R-HSA-9842860,Regulation of endogenous retroelements,2/349,37/3769,0.05405405405405406,0.5837528072485093,-0.8127116205810615,0.8701651324714971,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-177929,Signaling by EGFR,1/349,21/3769,0.047619047619047616,0.5142584254332104,-0.7129683318041362,0.8707827266180829,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-2022928,HS-GAG biosynthesis,1/349,21/3769,0.047619047619047616,0.5142584254332104,-0.7129683318041362,0.8707827266180829,0.995170154694874,0.9910673490027657,HS3ST1,1
R-HSA-373752,Netrin-1 signaling,1/349,21/3769,0.047619047619047616,0.5142584254332104,-0.7129683318041362,0.8707827266180829,0.995170154694874,0.9910673490027657,TRPC7,1
R-HSA-212436,Generic Transcription Pathway,26/349,337/3769,0.0771513353115727,0.8331902085653796,-1.0249860570904934,0.8709058701511334,0.995170154694874,0.9910673490027657,PRDM1/MBD3/FKBP5/NAMPT/BCL6/POMC/GADD45A/TNFRSF10B/ZNF205/CDK2/CDKN1A/IL6/THBS1/NOTCH1/RUNX1/CITED2/TNFRSF10D/TNFRSF10C/NR2F1/SOCS3/ZNF775/TEAD4/ZNF442/CR1/ZIM2/H3C2,26
R-HSA-2262752,Cellular responses to stress,16/349,218/3769,0.07339449541284404,0.7926184905759576,-1.0075765453714904,0.872499824217402,0.995170154694874,0.9910673490027657,FKBP5/CCL2/LMNB1/CDK2/CDKN1A/CHAC1/HSPA12B/IL6/PARN/NOTCH1/LY96/CREB3L1/SHC1/CITED2/TUBB6/H3C2,16
R-HSA-68886,M Phase,6/349,93/3769,0.06451612903225806,0.6967372215546723,-0.9458623527907164,0.8740876218022472,0.995170154694874,0.9910673490027657,LMNB1/CEP131/PLK4/MZT2B/TUBB6/H3C2,6
R-HSA-382551,Transport of small molecules,25/349,327/3769,0.0764525993883792,0.8256442610166224,-1.0538038908901959,0.877535611685268,0.995170154694874,0.9910673490027657,SLC7A2/ABCB4/SLC38A5/SLC11A1/CP/TRPC7/ATP2A3/SLC17A6/SLC25A1/SLC39A14/SLC1A5/LSR/STEAP4/SLC26A1/RUNX1/CYGB/SLC29A4/SLC13A4/NGB/MYO5B/ANGPTL4/SLC9A4/SLC25A10/SLC4A5/CPTP,25
R-HSA-9816359,Maternal to zygotic transition (MZT),2/349,38/3769,0.05263157894736842,0.5683908912682852,-0.85413178331887,0.8797579996982529,0.995170154694874,0.9910673490027657,TEAD4/H3C2,2
R-HSA-1226099,Signaling by FGFR in disease,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-156842,Eukaryotic Translation Elongation,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,EEF1D,1
R-HSA-162599,Late Phase of HIV Life Cycle,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,VPS28,1
R-HSA-2129379,Molecules associated with elastic fibres,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-2428928,IRS-related events triggered by IGF1R,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-3371556,Cellular response to heat stress,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,HSPA12B,1
R-HSA-420092,Glucagon-type ligand receptors,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,ADCYAP1,1
R-HSA-70171,Glycolysis,1/349,22/3769,0.045454545454545456,0.4908830424589737,-0.764966055095355,0.8828149647211483,0.995170154694874,0.9910673490027657,HK2,1
R-HSA-112315,Transmission across Chemical Synapses,10/349,147/3769,0.06802721088435375,0.7346548934760151,-1.048215638457824,0.8875856329394284,0.995170154694874,0.9910673490027657,ACHE/CHRNA4/NCALD/GRIP2/GABRA6/CHRNA6/KCNJ16/CPLX1/TUBB6/SLC18A3,10
R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",2/349,39/3769,0.05128205128205128,0.5538167658511498,-0.8946357365984196,0.888693840262865,0.995170154694874,0.9910673490027657,LSR/ANGPTL4,2
R-HSA-72766,Translation,2/349,39/3769,0.05128205128205128,0.5538167658511498,-0.8946357365984196,0.888693840262865,0.995170154694874,0.9910673490027657,EEF1D/MRPL12,2
R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,2/349,39/3769,0.05128205128205128,0.5538167658511498,-0.8946357365984196,0.888693840262865,0.995170154694874,0.9910673490027657,RUNX1/H3C2,2
R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,3/349,54/3769,0.05555555555555555,0.5999681630054122,-0.9457299328555075,0.8890549565331314,0.995170154694874,0.9910673490027657,KIF26A/RAB43/TUBB6,3
R-HSA-9694516,SARS-CoV-2 Infection,5/349,82/3769,0.06097560975609756,0.6585016423230134,-0.9986517889624215,0.8891050806112928,0.995170154694874,0.9910673490027657,NOD1/TLR2/IFNA5/B2M/ISG15,5
R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,7/349,109/3769,0.06422018348623854,0.6935411792539629,-1.0370505827383192,0.8909190023449323,0.995170154694874,0.9910673490027657,CHRNA4/NCALD/GRIP2/GABRA6/CHRNA6/KCNJ16/TUBB6,7
R-HSA-112316,Neuronal System,17/349,235/3769,0.07234042553191489,0.7812351399134305,-1.1061991722833675,0.8923886030517991,0.995170154694874,0.9910673490027657,KCNG1/APBA2/PANX2/ACHE/CHRNA4/NCALD/LRFN1/LRRC4B/GRIP2/GABRA6/CHRNA6/KCNJ16/CPLX1/KCNK9/LRFN4/TUBB6/SLC18A3,17
R-HSA-190828,Gap junction trafficking,1/349,23/3769,0.043478260869565216,0.4695403014824966,-0.8150561582437826,0.8937297171397016,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-3214858,RMTs methylate histone arginines,1/349,23/3769,0.043478260869565216,0.4695403014824966,-0.8150561582437826,0.8937297171397016,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-6804756,Regulation of TP53 Activity through Phosphorylation,1/349,23/3769,0.043478260869565216,0.4695403014824966,-0.8150561582437826,0.8937297171397016,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-8964043,Plasma lipoprotein clearance,1/349,23/3769,0.043478260869565216,0.4695403014824966,-0.8150561582437826,0.8937297171397016,0.995170154694874,0.9910673490027657,LSR,1
R-HSA-9660821,ADORA2B mediated anti-inflammatory cytokines production,1/349,23/3769,0.043478260869565216,0.4695403014824966,-0.8150561582437826,0.8937297171397016,0.995170154694874,0.9910673490027657,IL6,1
R-HSA-975634,Retinoid metabolism and transport,1/349,23/3769,0.043478260869565216,0.4695403014824966,-0.8150561582437826,0.8937297171397016,0.995170154694874,0.9910673490027657,TTR,1
R-HSA-9830369,Kidney development,1/349,23/3769,0.043478260869565216,0.4695403014824966,-0.8150561582437826,0.8937297171397016,0.995170154694874,0.9910673490027657,FGF2,1
R-HSA-9645723,Diseases of programmed cell death,2/349,40/3769,0.05,0.5399713467048711,-0.9342729920242636,0.8970116616017475,0.995170154694874,0.9910673490027657,LMNB1/H3C2,2
R-HSA-212165,Epigenetic regulation of gene expression,4/349,70/3769,0.05714285714285714,0.6171101105198527,-1.0328466862108097,0.9004736070877656,0.995170154694874,0.9910673490027657,MBD3/THRSP/ANGPTL4/H3C2,4
R-HSA-9018519,Estrogen-dependent gene expression,3/349,56/3769,0.05357142857142857,0.5785407286123618,-1.0149444157676502,0.9031167589901566,0.995170154694874,0.9910673490027657,CTSD/RUNX1/H3C2,3
R-HSA-109606,Intrinsic Pathway for Apoptosis,1/349,24/3769,0.041666666666666664,0.4499761222540592,-0.8634085816909348,0.9036304989651806,0.995170154694874,0.9910673490027657,BAD,1
R-HSA-1296065,Inwardly rectifying K+ channels,1/349,24/3769,0.041666666666666664,0.4499761222540592,-0.8634085816909348,0.9036304989651806,0.995170154694874,0.9910673490027657,KCNJ16,1
R-HSA-157858,Gap junction trafficking and regulation,1/349,24/3769,0.041666666666666664,0.4499761222540592,-0.8634085816909348,0.9036304989651806,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-432040,Vasopressin regulates renal water homeostasis via Aquaporins,1/349,24/3769,0.041666666666666664,0.4499761222540592,-0.8634085816909348,0.9036304989651806,0.995170154694874,0.9910673490027657,MYO5B,1
R-HSA-6807070,PTEN Regulation,1/349,24/3769,0.041666666666666664,0.4499761222540592,-0.8634085816909348,0.9036304989651806,0.995170154694874,0.9910673490027657,MBD3,1
R-HSA-9634597,GPER1 signaling,1/349,24/3769,0.041666666666666664,0.4499761222540592,-0.8634085816909348,0.9036304989651806,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-9709957,Sensory Perception,9/349,138/3769,0.06521739130434782,0.7043104522237448,-1.1303618702887932,0.9051363133573862,0.995170154694874,0.9910673490027657,DHRS9/CDH23/TTR/CHRNA10/OR2AT4/RTP1/OR51E1/CALHM1/OR8A1,9
R-HSA-1483257,Phospholipid metabolism,5/349,85/3769,0.058823529411764705,0.6352604078880836,-1.08639477373763,0.9064326714147246,0.995170154694874,0.9910673490027657,ACHE/LPCAT1/PLD4/CPNE7/TNFAIP8L1,5
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",3/349,57/3769,0.05263157894736842,0.5683908912682852,-1.048767336854923,0.9095278452583349,0.995170154694874,0.9910673490027657,IL1RL1/RAC2/FGF2,3
R-HSA-8957322,Metabolism of steroids,3/349,57/3769,0.05263157894736842,0.5683908912682852,-1.048767336854923,0.9095278452583349,0.995170154694874,0.9910673490027657,POMC/CH25H/MVD,3
R-HSA-9006931,Signaling by Nuclear Receptors,8/349,126/3769,0.06349206349206349,0.685677900577614,-1.146266792457822,0.9097176973123544,0.995170154694874,0.9910673490027657,DHRS9/FKBP5/CTSD/PDK1/RUNX1/SHC1/CYP26C1/H3C2,8
R-HSA-1227986,Signaling by ERBB2,1/349,25/3769,0.04,0.43197707736389684,-0.9101711258506028,0.9126112615449273,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-427359,SIRT1 negatively regulates rRNA expression,1/349,25/3769,0.04,0.43197707736389684,-0.9101711258506028,0.9126112615449273,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-437239,Recycling pathway of L1,1/349,25/3769,0.04,0.43197707736389684,-0.9101711258506028,0.9126112615449273,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-6794361,Neurexins and neuroligins,1/349,25/3769,0.04,0.43197707736389684,-0.9101711258506028,0.9126112615449273,0.995170154694874,0.9910673490027657,APBA2,1
R-HSA-70326,Glucose metabolism,1/349,25/3769,0.04,0.43197707736389684,-0.9101711258506028,0.9126112615449273,0.995170154694874,0.9910673490027657,HK2,1
R-HSA-73728,RNA Polymerase I Promoter Opening,1/349,25/3769,0.04,0.43197707736389684,-0.9101711258506028,0.9126112615449273,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-9843970,Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex,1/349,25/3769,0.04,0.43197707736389684,-0.9101711258506028,0.9126112615449273,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-74160,Gene expression (Transcription),30/349,399/3769,0.07518796992481203,0.8119869875261219,-1.2685702227734306,0.9160807452117004,0.995170154694874,0.9910673490027657,PRDM1/MBD3/FKBP5/NAMPT/BCL6/POMC/GADD45A/ELL2/TNFRSF10B/ZNF205/CDK2/CDKN1A/IL6/THBS1/NOTCH1/THRSP/RUNX1/CITED2/ANGPTL4/TNFRSF10D/TNFRSF10C/NABP1/NR2F1/SOCS3/ZNF775/TEAD4/ZNF442/CR1/ZIM2/H3C2,30
R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,2/349,43/3769,0.046511627906976744,0.5022989271673218,-1.0484228723336448,0.9186233269755292,0.995170154694874,0.9910673490027657,TUBB6/ISG15,2
R-HSA-6806667,Metabolism of fat-soluble vitamins,1/349,26/3769,0.038461538461538464,0.41536257438836244,-0.9554731365959619,0.9207572737566849,0.995170154694874,0.9910673490027657,TTR,1
R-HSA-9821002,Chromatin modifications during the maternal to zygotic transition (MZT),1/349,26/3769,0.038461538461538464,0.41536257438836244,-0.9554731365959619,0.9207572737566849,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-9909396,Circadian clock,1/349,26/3769,0.038461538461538464,0.41536257438836244,-0.9554731365959619,0.9207572737566849,0.995170154694874,0.9910673490027657,NAMPT,1
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,2/349,44/3769,0.045454545454545456,0.4908830424589737,-1.0850153189118596,0.9248272524486721,0.995170154694874,0.9910673490027657,RAC2/FGF2,2
R-HSA-2555396,Mitotic Metaphase and Anaphase,2/349,44/3769,0.045454545454545456,0.4908830424589737,-1.0850153189118596,0.9248272524486721,0.995170154694874,0.9910673490027657,LMNB1/TUBB6,2
R-HSA-68882,Mitotic Anaphase,2/349,44/3769,0.045454545454545456,0.4908830424589737,-1.0850153189118596,0.9248272524486721,0.995170154694874,0.9910673490027657,LMNB1/TUBB6,2
R-HSA-9659379,Sensory processing of sound,2/349,44/3769,0.045454545454545456,0.4908830424589737,-1.0850153189118596,0.9248272524486721,0.995170154694874,0.9910673490027657,CDH23/CHRNA10,2
R-HSA-1592230,Mitochondrial biogenesis,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,ATP5F1D,1
R-HSA-162587,HIV Life Cycle,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,VPS28,1
R-HSA-2299718,Condensation of Prophase Chromosomes,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5578775,Ion homeostasis,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,ATP2A3,1
R-HSA-5625886,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,TNFRSF1B,1
R-HSA-5693607,Processing of DNA double-strand break ends,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-68616,Assembly of the ORC complex at the origin of replication,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-977444,GABA B receptor activation,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,KCNJ16,1
R-HSA-991365,Activation of GABAB receptors,1/349,27/3769,0.037037037037037035,0.3999787753369415,-0.9994284569459331,0.9281459222896576,0.995170154694874,0.9910673490027657,KCNJ16,1
R-HSA-556833,Metabolism of lipids,19/349,271/3769,0.07011070110701106,0.7571553939035092,-1.3254346260214867,0.9287090022278448,0.995170154694874,0.9910673490027657,ABCB4/SPHK2/ACHE/POMC/G0S2/HILPDA/CYP1B1/CH25H/PTGES/THRSP/LPCAT1/PLD4/DPEP2/MVD/ANGPTL4/FUT1/CPNE7/TNFAIP8L1/ACSL5,19
R-HSA-422356,Regulation of insulin secretion,2/349,45/3769,0.044444444444444446,0.47997453040432986,-1.1209368411677882,0.9305840924731713,0.995170154694874,0.9910673490027657,ADRA2A/GNA14,2
R-HSA-5619115,Disorders of transmembrane transporters,2/349,45/3769,0.044444444444444446,0.47997453040432986,-1.1209368411677882,0.9305840924731713,0.995170154694874,0.9910673490027657,ABCB4/CP,2
R-HSA-68875,Mitotic Prophase,2/349,45/3769,0.044444444444444446,0.47997453040432986,-1.1209368411677882,0.9305840924731713,0.995170154694874,0.9910673490027657,LMNB1/H3C2,2
R-HSA-199418,Negative regulation of the PI3K/AKT network,3/349,61/3769,0.04918032786885246,0.5311193574146272,-1.1792678694714651,0.9315028460683037,0.995170154694874,0.9910673490027657,IL1RL1/RAC2/FGF2,3
R-HSA-8856828,Clathrin-mediated endocytosis,3/349,61/3769,0.04918032786885246,0.5311193574146272,-1.1792678694714651,0.9315028460683037,0.995170154694874,0.9910673490027657,TRIP10/IL7R/SLC18A3,3
R-HSA-69278,"Cell Cycle, Mitotic",9/349,145/3769,0.06206896551724138,0.6703092579784606,-1.2931585217595851,0.9318688783654383,0.995170154694874,0.9910673490027657,LMNB1/CDK2/CDKN1A/CEP131/PLK4/MZT2B/CDT1/TUBB6/H3C2,9
R-HSA-597592,Post-translational protein modification,32/349,430/3769,0.07441860465116279,0.8036782834677151,-1.3814954802871664,0.932498861997093,0.995170154694874,0.9910673490027657,TMEM132A/PLAUR/CP/TIMP1/NOD1/VNN2/CISH/CDKN1A/VGF/IL6/THBS1/SPTBN5/RAB20/TPGS1/LYPD6B/FBXW5/JOSD2/AMDHD2/ADAMTS9/FBXO40/MELTF/MVD/RAB24/SPSB1/RAB43/SPSB4/TUBB6/LY6H/SOCS3/NTNG2/SERPINA1/ADAMTSL2,32
R-HSA-1221632,Meiotic synapsis,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,LMNB1,1
R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-212300,PRC2 methylates histones and DNA,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-382556,ABC-family proteins mediated transport,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,ABCB4,1
R-HSA-5250924,B-WICH complex positively regulates rRNA expression,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5334118,DNA methylation,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5619102,SLC transporter disorders,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,CP,1
R-HSA-6802952,Signaling by BRAF and RAF1 fusions,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-73772,RNA Polymerase I Promoter Escape,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-8986944,Transcriptional Regulation by MECP2,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,FKBP5,1
R-HSA-9710421,Defective pyroptosis,1/349,28/3769,0.03571428571428571,0.3856938190749079,-1.0421378129640775,0.9348474383561755,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-8856688,Golgi-to-ER retrograde transport,2/349,46/3769,0.043478260869565216,0.4695403014824966,-1.1562184610596036,0.935923159668288,0.995170154694874,0.9910673490027657,KIF26A/TUBB6,2
R-HSA-8856825,Cargo recognition for clathrin-mediated endocytosis,2/349,46/3769,0.043478260869565216,0.4695403014824966,-1.1562184610596036,0.935923159668288,0.995170154694874,0.9910673490027657,IL7R/SLC18A3,2
R-HSA-9609690,HCMV Early Events,2/349,46/3769,0.043478260869565216,0.4695403014824966,-1.1562184610596036,0.935923159668288,0.995170154694874,0.9910673490027657,TUBB6/H3C2,2
R-HSA-9612973,Autophagy,2/349,46/3769,0.043478260869565216,0.4695403014824966,-1.1562184610596036,0.935923159668288,0.995170154694874,0.9910673490027657,VPS28/TUBB6,2
R-HSA-1266738,Developmental Biology,42/349,551/3769,0.07622504537205081,0.8231868080437236,-1.4346717656318149,0.9378068135623281,0.995170154694874,0.9910673490027657,CACNA1G/ZIC2/TRPC7/MBD3/ADAM11/EDN1/COL5A3/COL9A3/LIMK1/PLXNA1/POMC/CDK2/EDN3/CDKN1A/CNTN6/DSC2/IRF4/SPTBN5/FGF2/BCL2A1/NOTCH1/CPB1/ZIC3/RUNX1/SHC1/NTN3/SOX17/OTX2/MESP1/ANGPTL4/EFNA1/TUBB6/BHLHA15/LIMK2/EPHB3/PKP3/NR2F2/COL4A1/TEAD4/CRIPTO/ITGB3/H3C2,42
R-HSA-383280,Nuclear Receptor transcription pathway,1/349,29/3769,0.034482758620689655,0.37239403221025585,-1.0836907587889757,0.9409255575792962,0.995170154694874,0.9910673490027657,NR2F1,1
R-HSA-445717,Aquaporin-mediated transport,1/349,29/3769,0.034482758620689655,0.37239403221025585,-1.0836907587889757,0.9409255575792962,0.995170154694874,0.9910673490027657,MYO5B,1
R-HSA-9609507,Protein localization,1/349,29/3769,0.034482758620689655,0.37239403221025585,-1.0836907587889757,0.9409255575792962,0.995170154694874,0.9910673490027657,BAG6,1
R-HSA-9692914,SARS-CoV-1-host interactions,1/349,29/3769,0.034482758620689655,0.37239403221025585,-1.0836907587889757,0.9409255575792962,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-983705,Signaling by the B Cell Receptor (BCR),1/349,29/3769,0.034482758620689655,0.37239403221025585,-1.0836907587889757,0.9409255575792962,0.995170154694874,0.9910673490027657,BLNK,1
R-HSA-8939211,ESR-mediated signaling,5/349,93/3769,0.053763440860215055,0.5806143512955603,-1.3080441274192047,0.9415999739597617,0.995170154694874,0.9910673490027657,FKBP5/CTSD/RUNX1/SHC1/H3C2,5
R-HSA-71291,Metabolism of amino acids and derivatives,6/349,108/3769,0.05555555555555555,0.5999681630054122,-1.3472918334848234,0.9442619935513856,0.995170154694874,0.9910673490027657,DUOX1/HDC/GADL1/GPT/SLC25A10/BCKDHA,6
R-HSA-936837,Ion transport by P-type ATPases,1/349,30/3769,0.03333333333333333,0.3599808978032474,-1.1241672747740648,0.9464381191848645,0.995170154694874,0.9910673490027657,ATP2A3,1
R-HSA-2187338,Visual phototransduction,2/349,49/3769,0.04081632653061224,0.440792936085609,-1.2585032063927502,0.9497034440277594,0.995170154694874,0.9910673490027657,DHRS9/TTR,2
R-HSA-112043,PLC beta mediated events,1/349,31/3769,0.03225806451612903,0.34836861077733616,-1.1636390902110478,0.9514376100659778,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-1296072,Voltage gated Potassium channels,1/349,31/3769,0.03225806451612903,0.34836861077733616,-1.1636390902110478,0.9514376100659778,0.995170154694874,0.9910673490027657,KCNG1,1
R-HSA-157579,Telomere Maintenance,1/349,31/3769,0.03225806451612903,0.34836861077733616,-1.1636390902110478,0.9514376100659778,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-1638091,Heparan sulfate/heparin (HS-GAG) metabolism,1/349,31/3769,0.03225806451612903,0.34836861077733616,-1.1636390902110478,0.9514376100659778,0.995170154694874,0.9910673490027657,HS3ST1,1
R-HSA-5578749,Transcriptional regulation by small RNAs,1/349,31/3769,0.03225806451612903,0.34836861077733616,-1.1636390902110478,0.9514376100659778,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5610787,Hedgehog 'off' state,1/349,31/3769,0.03225806451612903,0.34836861077733616,-1.1636390902110478,0.9514376100659778,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,1/349,31/3769,0.03225806451612903,0.34836861077733616,-1.1636390902110478,0.9514376100659778,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-194315,Signaling by Rho GTPases,19/349,282/3769,0.0673758865248227,0.7276209636448617,-1.518893652034163,0.9529676961047294,0.995170154694874,0.9910673490027657,SLC1A5/LIMK1/LMNB1/PLXNA1/ARAP3/TRIP10/RAC2/ARHGEF16/HINT2/S100A8/RHPN1/S100A9/PPP1R14A/RAC3/TUBB6/SCRIB/LIMK2/NOXA1/H3C2,19
R-HSA-112040,G-protein mediated events,1/349,32/3769,0.03125,0.33748209169054444,-1.2021707855468369,0.9559716587783837,0.995170154694874,0.9910673490027657,GNA14,1
R-HSA-427413,NoRC negatively regulates rRNA expression,1/349,32/3769,0.03125,0.33748209169054444,-1.2021707855468369,0.9559716587783837,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5250941,Negative epigenetic regulation of rRNA expression,1/349,32/3769,0.03125,0.33748209169054444,-1.2021707855468369,0.9559716587783837,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-9925563,Developmental Lineage of Pancreatic Ductal Cells,1/349,32/3769,0.03125,0.33748209169054444,-1.2021707855468369,0.9559716587783837,0.995170154694874,0.9910673490027657,COL5A3,1
R-HSA-422475,Axon guidance,15/349,234/3769,0.0641025641025641,0.6922709573139372,-1.552518603518414,0.9581574308159029,0.995170154694874,0.9910673490027657,CACNA1G/TRPC7/COL5A3/COL9A3/LIMK1/PLXNA1/CNTN6/SPTBN5/SHC1/EFNA1/TUBB6/LIMK2/EPHB3/COL4A1/ITGB3,15
R-HSA-1483255,PI Metabolism,1/349,33/3769,0.030303030303030304,0.3272553616393158,-1.2398207166758823,0.9600834840623934,0.995170154694874,0.9910673490027657,TNFAIP8L1,1
R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),1/349,33/3769,0.030303030303030304,0.3272553616393158,-1.2398207166758823,0.9600834840623934,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-6802957,Oncogenic MAPK signaling,1/349,33/3769,0.030303030303030304,0.3272553616393158,-1.2398207166758823,0.9600834840623934,0.995170154694874,0.9910673490027657,ITGB3,1
R-HSA-9663891,Selective autophagy,1/349,33/3769,0.030303030303030304,0.3272553616393158,-1.2398207166758823,0.9600834840623934,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",19/349,287/3769,0.06620209059233449,0.7149446402364147,-1.60476293054179,0.9614091661227626,0.995170154694874,0.9910673490027657,SLC1A5/LIMK1/LMNB1/PLXNA1/ARAP3/TRIP10/RAC2/ARHGEF16/HINT2/S100A8/RHPN1/S100A9/PPP1R14A/RAC3/TUBB6/SCRIB/LIMK2/NOXA1/H3C2,19
R-HSA-9012999,RHO GTPase cycle,12/349,197/3769,0.06091370558375635,0.6578331127368988,-1.5756888957962085,0.9620653365411611,0.995170154694874,0.9910673490027657,SLC1A5/LMNB1/PLXNA1/ARAP3/TRIP10/RAC2/ARHGEF16/HINT2/RHPN1/RAC3/SCRIB/NOXA1,12
R-HSA-111885,Opioid Signalling,2/349,53/3769,0.03773584905660377,0.4075255446829215,-1.3874738927689554,0.9637412849942693,0.995170154694874,0.9910673490027657,POMC/GNA14,2
R-HSA-168255,Influenza Infection,1/349,34/3769,0.029411764705882353,0.3176302039440418,-1.2766417946192115,0.9638123020662009,0.995170154694874,0.9910673490027657,ISG15,1
R-HSA-2500257,Resolution of Sister Chromatid Cohesion,1/349,34/3769,0.029411764705882353,0.3176302039440418,-1.2766417946192115,0.9638123020662009,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9006925,Intracellular signaling by second messengers,6/349,116/3769,0.05172413793103448,0.5585910483153839,-1.5424120246699098,0.9651102565429319,0.995170154694874,0.9910673490027657,BAD/MBD3/IL1RL1/CDKN1A/RAC2/FGF2,6
R-HSA-1296071,Potassium Channels,3/349,71/3769,0.04225352112676056,0.4563138141167925,-1.4772334289861975,0.966753963524754,0.995170154694874,0.9910673490027657,KCNG1/KCNJ16/KCNK9,3
R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,1/349,35/3769,0.02857142857142857,0.3085550552599263,-1.3126821468628191,0.9671936960632279,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5619507,Activation of HOX genes during differentiation,1/349,35/3769,0.02857142857142857,0.3085550552599263,-1.3126821468628191,0.9671936960632279,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-5693538,Homology Directed Repair,1/349,35/3769,0.02857142857142857,0.3085550552599263,-1.3126821468628191,0.9671936960632279,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-73886,Chromosome Maintenance,1/349,35/3769,0.02857142857142857,0.3085550552599263,-1.3126821468628191,0.9671936960632279,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-163685,Integration of energy metabolism,2/349,55/3769,0.03636363636363636,0.39270643396717897,-1.4491528076096496,0.9692672128262141,0.995170154694874,0.9910673490027657,ADRA2A/GNA14,2
R-HSA-3247509,Chromatin modifying enzymes,2/349,55/3769,0.03636363636363636,0.39270643396717897,-1.4491528076096496,0.9692672128262141,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,1/349,36/3769,0.027777777777777776,0.2999840815027061,-1.3479856812355782,0.9702599521087376,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-2467813,Separation of Sister Chromatids,1/349,36/3769,0.027777777777777776,0.2999840815027061,-1.3479856812355782,0.9702599521087376,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9009391,Extra-nuclear estrogen signaling,1/349,36/3769,0.027777777777777776,0.2999840815027061,-1.3479856812355782,0.9702599521087376,0.995170154694874,0.9910673490027657,SHC1,1
R-HSA-5653656,Vesicle-mediated transport,13/349,216/3769,0.06018518518518518,0.64996550992253,-1.6923696108844397,0.9710658485854391,0.995170154694874,0.9910673490027657,MSR1/KIF26A/TRIP10/SPTBN5/VPS28/DENND2D/IL7R/TRAPPC12/RAB43/TUBB6/COL4A1/SLC18A3/SERPINA1,13
R-HSA-3214847,HATs acetylate histones,1/349,37/3769,0.02702702702702703,0.29187640362425465,-1.3825925690406002,0.9730403637653278,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-8953854,Metabolism of RNA,3/349,74/3769,0.04054054054054054,0.437814605436382,-1.5600671947773646,0.9734127997536413,0.995170154694874,0.9910673490027657,ZFP36/PARN/ADAT3,3
R-HSA-438064,Post NMDA receptor activation events,1/349,38/3769,0.02631578947368421,0.2841954456341426,-1.4165396609095096,0.9755615087401135,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-5663220,RHO GTPases Activate Formins,1/349,38/3769,0.02631578947368421,0.2841954456341426,-1.4165396609095096,0.9755615087401135,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9662360,Sensory processing of sound by inner hair cells of the cochlea,1/349,38/3769,0.02631578947368421,0.2841954456341426,-1.4165396609095096,0.9755615087401135,0.995170154694874,0.9910673490027657,CDH23,1
R-HSA-4839726,Chromatin organization,2/349,58/3769,0.034482758620689655,0.37239403221025585,-1.5385467305271878,0.9760653016267238,0.995170154694874,0.9910673490027657,MBD3/H3C2,2
R-HSA-9675108,Nervous system development,15/349,249/3769,0.060240963855421686,0.6505678875962302,-1.8224107265349363,0.9786536394380829,0.995170154694874,0.9910673490027657,CACNA1G/TRPC7/COL5A3/COL9A3/LIMK1/PLXNA1/CNTN6/SPTBN5/SHC1/EFNA1/TUBB6/LIMK2/EPHB3/COL4A1/ITGB3,15
R-HSA-1632852,Macroautophagy,1/349,40/3769,0.025,0.26998567335243556,-1.482587365574474,0.9799202138213199,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-211000,Gene Silencing by RNA,1/349,40/3769,0.025,0.26998567335243556,-1.482587365574474,0.9799202138213199,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-9013408,RHOG GTPase cycle,1/349,40/3769,0.025,0.26998567335243556,-1.482587365574474,0.9799202138213199,0.995170154694874,0.9910673490027657,ARHGEF16,1
R-HSA-9678108,SARS-CoV-1 Infection,1/349,40/3769,0.025,0.26998567335243556,-1.482587365574474,0.9799202138213199,0.995170154694874,0.9910673490027657,RUNX1,1
R-HSA-9013148,CDC42 GTPase cycle,3/349,78/3769,0.038461538461538464,0.41536257438836244,-1.6665448258021012,0.9803474894803961,0.995170154694874,0.9910673490027657,ARAP3/ARHGEF16/SCRIB,3
R-HSA-5576891,Cardiac conduction,3/349,80/3769,0.0375,0.4049785100286533,-1.718218633546998,0.983132442435422,0.995170154694874,0.9910673490027657,ATP2A3/KCNE4/KCNK9,3
R-HSA-199991,Membrane Trafficking,11/349,200/3769,0.055,0.5939684813753582,-1.8847622679286757,0.9834083653861254,0.995170154694874,0.9910673490027657,KIF26A/TRIP10/SPTBN5/VPS28/DENND2D/IL7R/TRAPPC12/RAB43/TUBB6/SLC18A3/SERPINA1,11
R-HSA-5358351,Signaling by Hedgehog,1/349,43/3769,0.023255813953488372,0.2511494635836609,-1.5774770704626457,0.9850481152310763,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-9013404,RAC2 GTPase cycle,1/349,43/3769,0.023255813953488372,0.2511494635836609,-1.5774770704626457,0.9850481152310763,0.995170154694874,0.9910673490027657,RAC2,1
R-HSA-1640170,Cell Cycle,9/349,174/3769,0.05172413793103448,0.5585910483153839,-1.9042388468873086,0.9852413939006663,0.995170154694874,0.9910673490027657,LMNB1/CDK2/CDKN1A/CEP131/PLK4/MZT2B/CDT1/TUBB6/H3C2,9
R-HSA-2559580,Oxidative Stress Induced Senescence,1/349,44/3769,0.022727272727272728,0.24544152122948684,-1.60809318242923,0.9864486004120625,0.995170154694874,0.9910673490027657,H3C2,1
R-HSA-442755,Activation of NMDA receptors and postsynaptic events,1/349,44/3769,0.022727272727272728,0.24544152122948684,-1.60809318242923,0.9864486004120625,0.995170154694874,0.9910673490027657,TUBB6,1
R-HSA-5693532,DNA Double-Strand Break Repair,1/349,45/3769,0.022222222222222223,0.23998726520216493,-1.6382395171028188,0.9877182483197645,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-73894,DNA Repair,2/349,66/3769,0.030303030303030304,0.3272553616393158,-1.761166696790651,0.9878382904166656,0.995170154694874,0.9910673490027657,CDK2/ISG15,2
R-HSA-416482,G alpha (12/13) signalling events,1/349,46/3769,0.021739130434782608,0.2347701507412483,-1.6679360960682514,0.9888692502897973,0.995170154694874,0.9910673490027657,ARHGEF16,1
R-HSA-69481,G2/M Checkpoints,1/349,46/3769,0.021739130434782608,0.2347701507412483,-1.6679360960682514,0.9888692502897973,0.995170154694874,0.9910673490027657,CDK2,1
R-HSA-2672351,Stimuli-sensing channels,1/349,47/3769,0.02127659574468085,0.22977504115100894,-1.6972016282521558,0.9899126646461929,0.995170154694874,0.9910673490027657,TRPC7,1
R-HSA-69620,Cell Cycle Checkpoints,2/349,70/3769,0.02857142857142857,0.3085550552599263,-1.865174922329805,0.9913741524105903,0.995170154694874,0.9910673490027657,CDK2/CDKN1A,2
R-HSA-1430728,Metabolism,53/349,747/3769,0.07095046854082998,0.7662244009466711,-2.2791208646473624,0.992020249644443,0.995170154694874,0.9910673490027657,HS3ST1/ABCB4/CYP3A43/SPHK2/MTHFD2/ITPKC/ACHE/ATP5F1D/PYGL/NME3/HAS1/NAMPT/VNN2/POMC/TTR/CHST3/G0S2/CHAC1/CHSY1/HILPDA/DUOX1/CYP1B1/CH25H/HDC/GADL1/SLC26A1/PTGES/ADRA2A/THRSP/PDK1/LPCAT1/GNA14/HK2/CYGB/PLD4/GLYATL1/DPEP2/MVD/GPT/ANGPTL4/NUDT8/GLRX/FUT1/CPNE7/OPLAH/SLC25A10/TNFAIP8L1/HYAL3/CYP26C1/ACSL5/PNP/ACY1/BCKDHA,53
R-HSA-5688426,Deubiquitination,2/349,71/3769,0.028169014084507043,0.30420920941119495,-1.8905122883871015,0.9920877810739479,0.995170154694874,0.9910673490027657,NOD1/JOSD2,2
R-HSA-8980692,RHOA GTPase cycle,2/349,72/3769,0.027777777777777776,0.2999840815027061,-1.9155987567521175,0.9927436848258395,0.995170154694874,0.9910673490027657,ARAP3/RHPN1,2
R-HSA-397014,Muscle contraction,4/349,109/3769,0.03669724770642202,0.3963092452879788,-2.042877563268614,0.9931453934442231,0.995170154694874,0.9910673490027657,CACNA1G/ATP2A3/KCNE4/KCNK9,4
R-HSA-9013149,RAC1 GTPase cycle,3/349,94/3769,0.031914893617021274,0.3446625617265134,-2.055205917654247,0.9943725472389902,0.995385146574264,0.991281454531312,SLC1A5/ARAP3/NOXA1,3
R-HSA-983712,Ion channel transport,2/349,87/3769,0.022988505747126436,0.24826268814017058,-2.265890655340217,0.9980568185628382,0.9980568185628382,0.9939421119702732,TRPC7/ATP2A3,2
